RECQ helicase (WRN) inhibitors for Werner syndrome and their usage
By developing WRN inhibitor compounds to inhibit WRN helicase activity, the problems of nuclease cleavage and chromosome damage in amplified TA repeat sequences in mismatch repair defective cancers have been solved, providing a new and effective method for treating MSI-H cancers.
Patent Information
- Application Number
- CN202580029027.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2024-04-19
- Filing Date
- 2025-04-18
- Publication Date
- 2026-11-17
AI Technical Summary
Existing technologies are unable to effectively inhibit WRN helicase activity, resulting in poor treatment outcomes for mismatch repair-deficient cancers, especially in microsatellite highly unstable (MSI-H) cancers, where amplified TA repeat sequences are susceptible to nuclease cleavage and chromosome damage.
To develop a WRN inhibitor compound that inhibits WRN helicase activity for the treatment of mismatch repair deficient cancers, particularly microsatellite highly unstable (MSI-H) cancers such as colorectal cancer, gastric cancer, prostate cancer, and endometrial cancer.
It effectively inhibits WRN helicase activity, reduces nuclease cleavage and chromosome damage of amplified TA repeat sequences, and provides a new strategy for treating mismatch repair defective cancers, especially showing significant therapeutic effects on MSI-H cancers.
Smart Images

Figure SMS_1 
Figure SMS_3 
Figure SMS_55
Abstract
Description
Cross-references
[0001] This patent application claims the benefit of International Application No. PCT / CN2024 / 088943, filed on April 19, 2024, which is incorporated herein by reference in its entirety. Background Technology
[0002] Loss of DNA mismatch repair is a common initiation event in cancer development. Genomic damage resulting from defects in mismatch repair mechanisms (dMMR) is known as microsatellite instability (MSI). MSI is commonly seen in colorectal cancer, endometrial cancer, ovarian cancer, gastric cancer, and other cancer types. Mutations or silencing of MMR genes (including MLH1, MSH2, MSH6, and PMS2) impair a cell's ability to repair DNA mismatches. MSI can be assessed using molecular assays of five microsatellites, including two single nucleotides (BAT25 and BAT26) and three dinucleotides (D2S123, D5S346, and D17S250). If two or more microsatellite markers show instability, the tumor is labeled as microsatellite highly unstable (MSI-H); if only one microsatellite marker shows instability, the tumor is labeled as microsatellite poorly unstable (MSI-L); and if none of the five microsatellite markers show instability, the tumor is labeled as microsatellite stable (MSS).
[0003] WRN (Warner syndrome RecQ helicase) comprises an exonuclease domain and an ATP-dependent helicase domain. Localized in the cell nucleus, it unwinds double-stranded DNA, particularly its secondary structures, during DNA replication, damage, and repair. WRN helicase activity has been shown to be crucial for the survival of mismatch repair-deficient cells (MSI cells). Dinucleotide TA repeat sequences have been shown to be selectively unstable and massively amplified in MSI cells. These amplified TA repeat sequences form secondary DNA structures that require WRN unwinding. In the absence of WRN proteins or inhibition of their helicase activity, amplified TA repeat sequences in MSI cells are susceptible to nuclease cleavage and chromosomal damage. Therefore, WRN inhibition is a promising therapeutic strategy for treating mismatch repair-deficient cancers, and there is an urgent need to develop novel compounds with WRN-inhibiting effects that can serve as WRN inhibitors. Summary of the Invention
[0004] This article discloses compounds that are WRN inhibitors, or pharmaceutically acceptable salts or stereoisomers thereof.
[0005] This article discloses a compound of formula (I), or a pharmaceutically acceptable salt or stereoisomer thereof: As defined in this paper, equation (I).
[0006] This article also discloses a pharmaceutical composition comprising the compound disclosed herein, or a pharmaceutically acceptable salt or stereoisomer thereof, and a pharmaceutically acceptable excipient.
[0007] This article also discloses a method for inhibiting WRN activity in subjects in need, comprising administering the compound disclosed herein, or a pharmaceutically acceptable salt or stereoisomer thereof, to the subject in need.
[0008] This article also discloses a method for treating a disease or condition in a subject in need, comprising administering the disclosed compound, or a pharmaceutically acceptable salt or stereoisomer thereof, to the subject in need.
[0009] In some embodiments, the disease or condition is cancer. In some embodiments, the cancer is a solid tumor. In some embodiments, the cancer is characterized by microsatellite high instability (MSI-H) or mismatch repair deficiency (dMMR). In some embodiments, cancers characterized by microsatellite high instability (MSI-H) or mismatch repair deficiency (dMMR) are selected from colorectal cancer, gastric cancer, prostate cancer, and endometrial cancer. In some embodiments, cancers characterized by microsatellite high instability (MSI-H) or mismatch repair deficiency (dMMR) are selected from endometrial cancer of the uterine corpus, colonic adenocarcinoma, gastric adenocarcinoma, rectal adenocarcinoma, adrenocortical carcinoma, uterine carcinosarcoma, cervical squamous cell carcinoma, cervical endometrial adenocarcinoma, esophageal cancer, breast cancer, renal clear cell carcinoma, prostate cancer, and ovarian serous cystadenocarcinoma. By incorporating references
[0010] All publications, patents and patent applications mentioned in this specification are incorporated herein by reference to the same extent that each individual publication, patent or patent application is specifically and individually indicated to be incorporated by reference. Detailed Implementation definition
[0011] In the following description, certain specific details are set forth to provide a thorough understanding of various embodiments. However, those skilled in the art will understand that the invention can be practiced without these details. In other instances, well-known structures are not shown or described in detail to avoid unnecessarily obscuring the description of the embodiments. Unless the context requires otherwise, throughout the specification and the following claims, the word “comprise” and its variations such as “comprises” and “comprising” should be interpreted in an open, inclusive sense, meaning “including but not limited to”. Furthermore, the headings provided herein are for convenience only and do not constitute an explanation of the scope or meaning of the claimed invention.
[0012] Throughout this specification, references to "some embodiments" or "an embodiment" mean that a particular feature, structure, or characteristic described in connection with an embodiment is included in at least one embodiment. Therefore, the phrase "in one embodiment" or "in an embodiment" appearing throughout this specification does not necessarily refer to the same embodiment. Furthermore, a particular feature, structure, or characteristic may be combined in one or more embodiments in any suitable manner. And, as used in this specification and the appended claims, the singular forms "a / an," "a / an," and "the" include plural references unless expressly stated otherwise. It should also be noted that the term "or" is generally used in its meaning including "and / or" unless expressly stated otherwise.
[0013] Unless otherwise indicated, the following terms have the following meanings as used herein:
[0014] "Oxytochemical" refers to the compound oxygen (O).
[0015] The "carboxyl group" refers to -COOH.
[0016] "Cyano" refers to -CN.
[0017] "alkyl" refers to a monovalent group of a straight-chain or branched saturated hydrocarbon having one to ten carbon atoms, more preferably one to six carbon atoms. Examples include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, 2-methyl-1-propyl, 2-methyl-2-propyl, 2-methyl-1-butyl, 3-methyl-1-butyl, 2-methyl-3-butyl, 2,2-dimethyl-1-propyl, 2-methyl-1-pentyl, 3-methyl-1-pentyl, 4-methyl-1-pentyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 2,2-dimethyl-1-butyl, 3,3-dimethyl-1-butyl, 2-ethyl-1-butyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, tert-pentyl, and hexyl, as well as longer alkyl groups such as heptyl and octyl. Whenever used herein, numerical ranges such as “C1-C6 alkyl” or “C1-6 alkyl” mean that an alkyl group can consist of 1, 2, 3, 4, 5, or 6 carbon atoms, although this definition also covers the use of the term “alkyl” when no numerical range is specified. In some embodiments, the alkyl group is C1- 10Alkyl group. In some embodiments, the alkyl group is C1-6 alkyl. In some embodiments, the alkyl group is C1-5 alkyl. In some embodiments, the alkyl group is C1-4 alkyl. In some embodiments, the alkyl group is C1-3 alkyl. Unless otherwise specifically stated in this specification, the alkyl group may optionally be substituted with, for example, oxo, halogen, amino, nitrile, nitro, hydroxy, haloalkyl, alkoxy, carboxyl, carboxylic acid ester, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, etc. In some embodiments, the alkyl group is optionally substituted with oxo, halogen, -CN, -COOH, -COOMe, -OH, -OMe, -NH2, or -NO2. In some embodiments, the alkyl group is optionally substituted with halogen, -CN, -OH, or -OMe. In some embodiments, the alkyl group is optionally substituted with halogen.
[0018] "alkylidenyl" is an alkenyl group as defined above, linked by a terminal divalent carbon. For example, in the following compounds: The alkylidene group is surrounded by the box indicated by the arrow.
[0019] "Alkenyl" refers to a monovalent group of a straight-chain or branched hydrocarbon having one or more carbon-carbon double bonds and having two to ten carbon atoms, more preferably two to six carbon atoms. This group may be in a cis or trans conformation around the double bond and should be understood to include both isomers. Examples include, but are not limited to, vinyl (-CH=CH2), 1-propenyl (-CH2CH=CH2), isopropenyl (-C(CH3)=CH2), butenyl, 1,3-butadienyl, etc. Whenever it appears herein, numerical ranges such as "C2-C6 alkenyl" or "C2-6 alkenyl" mean that the alkenyl group may consist of 2, 3, 4, 5, or 6 carbon atoms, although this definition also covers the occurrence of the term "alkenyl" when no numerical range is specified. Unless otherwise specifically stated in this specification, the alkenyl group may optionally be substituted with, for example, oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, carboxyl, carboxylic acid ester, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, etc. In some embodiments, the alkenyl group is optionally substituted with oxo, halogen, -CN, -COOH, -COOMe, -OH, -OMe, -NH2, or -NO2. In some embodiments, the alkenyl group is optionally substituted with halogen, -CN, -OH, or -OMe. In some embodiments, the alkenyl group is optionally substituted with halogen.
[0020] "Alynyl" refers to a monovalent group of a straight-chain or branched hydrocarbon having one or more carbon-carbon triple bonds and having two to ten carbon atoms, more preferably two to six carbon atoms. Examples include, but are not limited to, ethynyl, 2-propynyl, 2-butynyl, 1,3-butadiynyl, etc. Whenever it appears herein, numerical ranges such as "C2-C6 alkynyl" or "C2-6 alkynyl" mean that the alkynyl group can consist of 2, 3, 4, 5, or 6 carbon atoms, although this definition also covers the occurrence of the term "alkynyl" when no numerical range is specified. Unless otherwise specifically stated in this specification, the alkynyl group may optionally be substituted with, for example, oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, carboxyl, carboxylic acid ester, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, etc. In some embodiments, the alkynyl group is optionally substituted with an oxo group, a halogen group, -CN, -COOH, COOMe, -OH, -OMe, -NH2, or -NO2. In some embodiments, the alkynyl group is optionally substituted with a halogen group, -CN, -OH, or -OMe. In some embodiments, the alkynyl group is optionally substituted with a halogen group.
[0021] "alkylene" refers to a straight-chain or branched divalent hydrocarbon chain. Unless otherwise specifically stated in this specification, alkylene may optionally be substituted with, for example, oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, carboxyl, carboxylic acid ester, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, etc. In some embodiments, alkylene is optionally substituted with oxo, halogen, -CN, -COOH, COOMe, -OH, -OMe, -NH2, or -NO2. In some embodiments, alkylene is optionally substituted with halogen, -CN, -OH, or -OMe. In some embodiments, alkylene is optionally substituted with halogen.
[0022] "Alkoxy" refers to a group having the formula -O alkyl, wherein the alkyl group is as defined above. Unless otherwise specifically stated in this specification, an alkoxy group may optionally be substituted with, for example, oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, carboxyl, carboxylic acid ester, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, etc. In some embodiments, the alkoxy group is optionally substituted with halogen, -CN, -COOH, COOMe, -OH, -OMe, -NH2, or -NO2. In some embodiments, the alkoxy group is optionally substituted with halogen, -CN, -OH, or -OMe. In some embodiments, the alkoxy group is optionally substituted with halogen.
[0023] "Aryl" refers to a group derived from a hydrocarbon ring system containing 6 to 30 carbon atoms and at least one aromatic ring. Aryl groups can be monocyclic, bicyclic, tricyclic, or tetracyclic ring systems, which can include fused ring systems (where the aryl group is bonded to the aromatic ring atoms when fused with a cycloalkyl or heterocyclic alkyl ring) or bridged ring systems. In some embodiments, the aryl group is a 6- to 10-membered aryl group. In some embodiments, the aryl group is a 6-membered aryl (phenyl). Aryl groups include, but are not limited to, aryl groups derived from the following hydrocarbon ring systems: anthracene, naphthyl, phenanthrene, anthracene, azulene, benzene, chrysene, fluoranthene, fluorene, asymmetric indole, symmetric indole, indane, indene, naphthalene, phenalene, pleiadene, pyrene, and triphenylene. Unless otherwise specifically stated in this specification, the aryl group may optionally be substituted with, for example, halogen, amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, carboxyl, carboxylic acid ester, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, etc. In some embodiments, the aryl group is optionally substituted with halogen, methyl, ethyl, -CN, -COOH, COOMe, -CF3, -OH, -OMe, -NH2, or -NO2. In some embodiments, the aryl group is optionally substituted with halogen, methyl, ethyl, -CN, -CF3, -OH, or -OMe. In some embodiments, the aryl group is optionally substituted with halogen.
[0024] "Cycloalkyl" refers to a partially or fully saturated monocyclic or polycyclic carbon ring, which may include fused ring systems (where the cycloalkyl is bonded to non-aromatic ring atoms when fused with an aryl or heteroaryl ring), spirocyclic ring systems, or bridged ring systems. In some embodiments, the cycloalkyl is fully saturated. Representative cycloalkyl groups include, but are not limited to, those having three to fifteen carbon atoms (e.g., C3-C5). 15 Fully saturated cycloalkyl or C3-C 15 Cycloalkenyl), three to ten carbon atoms (e.g., C3-C) 10 Fully saturated cycloalkyl or C3-C 10Cycloalkyl groups are 3 to 10-membered fully saturated cycloalkyl groups or 3 to 10-membered cycloalkenyl groups. In some embodiments, the cycloalkyl group is 3 to 6-membered fully saturated cycloalkyl groups or 3 to 6-membered cycloalkenyl groups. In some embodiments, the cycloalkyl group is 5 to 6-membered fully saturated cycloalkyl groups or 5 to 6-membered cycloalkenyl groups. Monocyclic cycloalkyl groups include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Polycyclic cycloalkyl groups include, for example, adamantyl, norbornel, decahydronaphthyl, bicyclo[3.3.0]octane, bicyclo[4.3.0]nonane, cis-decahydronaphthyl, trans-decahydronaphthyl, bicyclo[2.1.1]hexane, bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, bicyclo[3.2.2]nonane, and bicyclo[3.3.2]decane, as well as 7,7-dimethyl-bicyclo[2.2.1]heptyl. Partially saturated cycloalkyl groups include, for example, cyclopentenyl, cyclohexenyl, cycloheptenyl, and cyclooctenyl. Unless otherwise specifically stated in this specification, cycloalkyl groups may optionally be substituted with, for example, oxo, halogen, amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, carboxyl, carboxyl ester, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, etc. In some embodiments, the cycloalkyl group is optionally substituted with an oxo, halogen, methyl, ethyl, -CN, -COOH, COOMe, -CF3, -OH, -OMe, -NH2, or -NO2. In some embodiments, the cycloalkyl group is optionally substituted with an oxo, halogen, methyl, ethyl, -CN, -CF3, -OH, or -OMe. In some embodiments, the cycloalkyl group is optionally substituted with a halogen.
[0025] "Halogen" or "halogen" refers to bromine, chlorine, fluorine, or iodine. In some embodiments, the halogen is fluorine or chlorine. In some embodiments, the halogen is fluorine.
[0026] "Halogenated alkyl" refers to an alkyl group as defined above that is substituted with one or more halogenated groups as defined above, such as trifluoromethyl, difluoromethyl, fluoromethyl, trichloromethyl, 2,2,2-trifluoroethyl, 1,2-difluoroethyl, 3-bromo-2-fluoropropyl, 1,2-dibromoethyl, etc.
[0027] "Hydroxyalkyl" refers to an alkyl group as defined above that is substituted with one or more hydroxyl groups. In some embodiments, the alkyl group is substituted with one hydroxyl group. In some embodiments, the alkyl group is substituted with one, two, or three hydroxyl groups. Hydroxyalkyl groups include, for example, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, or hydroxypentyl. In some embodiments, the hydroxyalkyl group is hydroxymethyl.
[0028] "Aminoalkyl" refers to an alkyl group as defined above that is substituted with one or more amines. In some embodiments, the alkyl group is substituted with one amine. In some embodiments, the alkyl group is substituted with one, two, or three amines. Aminoalkyl groups include, for example, aminomethyl, aminoethyl, aminopropyl, aminobutyl, or aminopentyl. In some embodiments, the aminoalkyl group is aminomethyl.
[0029] "Heteroalkyl" refers to an alkyl group in which one or more skeletal atoms of the alkyl group are selected from atoms other than carbon (e.g., oxygen, nitrogen (e.g., -NH-, -N(alkyl)-), sulfur, phosphorus, or combinations thereof). The heteroalkyl group is attached to the remainder of the molecule at a carbon atom of the heteroalkyl group. In one aspect, a heteroalkyl group is a C1-C6 heteroalkyl group, wherein the heteroalkyl group consists of 1 to 6 carbon atoms and one or more atoms other than carbon (e.g., oxygen, nitrogen (e.g., -NH-, -N(alkyl)-), sulfur, phosphorus, or combinations thereof), wherein the heteroalkyl group is attached to the remainder of the molecule at a carbon atom of the heteroalkyl group. Examples of such heteroalkyl groups are, for example, -CH2OCH3, -CH2CH2OCH3, -CH2CH2OCH2CH2OCH3, -CH(CH3)OCH3, -CH2NHCH3, -CH2N(CH3)2, -CH2CH2NHCH3, or -CH2CH2N(CH3)2. Unless otherwise specified in this specification, heteroalkyl groups are optionally substituted with, for example, oxo, halogen, amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, etc. In some embodiments, heteroalkyl groups are optionally substituted with oxo, halogen, methyl, ethyl, -CN, -CF3, -OH, -OMe, -NH2, or -NO2. In some embodiments, heteroalkyl groups are optionally substituted with oxo, halogen, methyl, ethyl, -CN, -CF3, -OH, or -OMe. In some embodiments, heteroalkyl groups are optionally substituted with halogens.
[0030] "Heterocyclic alkyl" refers to a 3- to 24-membered partially saturated or fully saturated cyclic group comprising 2 to 23 carbon atoms and 1 to 8 heteroatoms selected from the group consisting of nitrogen, oxygen, phosphorus, silicon, and sulfur. In some embodiments, the heterocyclic alkyl is fully saturated. In some embodiments, the heterocyclic alkyl comprises one to three heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur. In some embodiments, the heterocyclic alkyl comprises one to three heteroatoms selected from the group consisting of nitrogen and oxygen. In some embodiments, the heterocyclic alkyl comprises one to three nitrogen atoms. In some embodiments, the heterocyclic alkyl comprises one or two nitrogen atoms. In some embodiments, the heterocyclic alkyl comprises one nitrogen atom. In some embodiments, the heterocyclic alkyl comprises one nitrogen atom and one oxygen atom. Unless otherwise specified in this specification, heterocyclic alkyl groups can be monocyclic, bicyclic, tricyclic, or tetracyclic ring systems, which may include fused ring systems (where the heterocyclic alkyl group is bonded by non-aromatic ring atoms when fused with an aryl or heteroaryl ring), spirocyclic ring systems, or bridged ring systems; and the nitrogen, carbon, or sulfur atoms in the heterocyclic alkyl group may optionally be oxidized; the nitrogen atom may optionally be quaternized. Representative heterocyclic alkyl groups include, but are not limited to, those having two to fifteen carbon atoms (e.g., C2-C1). 15 Fully saturated heterocyclic alkyl or C2-C 15 Heterocyclic alkenyl groups, two to ten carbon atoms (e.g., C2-C) 10 Fully saturated heterocyclic alkyl or C2-C 10Heterocyclic alkyl groups consisting of two to eight carbon atoms (e.g., C2-C8 fully saturated heterocyclic alkyl or C2-C8 heterocyclic alkyl), two to seven carbon atoms (e.g., C2-C7 fully saturated heterocyclic alkyl or C2-C7 heterocyclic alkyl), two to six carbon atoms (e.g., C2-C6 fully saturated heterocyclic alkyl or C2-C6 heterocyclic alkyl), two to five carbon atoms (e.g., C2-C5 fully saturated heterocyclic alkyl or C2-C5 heterocyclic alkyl), or two to four carbon atoms (e.g., C2-C4 fully saturated heterocyclic alkyl or C2-C4 heterocyclic alkyl). Examples of such heterocyclic alkyl groups include, but are not limited to, aziridinyl, aziridine, oxacyclobutyl, dioxopentyl, thienyl[1,3]dithiaalkyl, decahydroisoquinolinyl, imidazolinyl, imidazoalkyl, isothiazolinyl, isoxazolinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperidinyl, 2-oxopiperidinyl, 2-oxopiperidinyl, oxazolinyl, piperidinyl, piperazinyl, 4-piperidinoneyl, pyrroleyl. Pyrazolyl, quinoline, thiazolyl, tetrahydrofuranyl, trithiayl, tetrahydropyranyl, thiomorpholinyl, thiomorpholinyl, 1-oxo-thiomorpholinyl, 1,1-dioxo-thiomorpholinyl, 1,3-dihydroisobenzofuran-1-yl, 3-oxo-1,3-dihydroisobenzofuran-1-yl, methyl-2-oxo-1,3-dioxacyclopenten-4-yl, and 2-oxo-1,3-dioxacyclopenten-4-yl. The term heterocyclic alkyl also includes all cyclic forms of carbohydrates, including but not limited to monosaccharides, disaccharides, and oligosaccharides. In some embodiments, the heterocyclic alkyl has 2 to 10 carbons in the ring. It should be understood that when referring to the number of carbon atoms in a heterocyclic alkyl, the number of carbon atoms in the heterocyclic alkyl is different from the total number of atoms constituting the heterocyclic alkyl (including heteroatoms) (i.e., the skeletal atoms of the heterocyclic alkyl ring). In some embodiments, the heterocyclic alkyl group is a 3- to 8-membered heterocyclic alkyl group. In some embodiments, the heterocyclic alkyl group is a 3- to 7-membered heterocyclic alkyl group. In some embodiments, the heterocyclic alkyl group is a 3- to 6-membered heterocyclic alkyl group. In some embodiments, the heterocyclic alkyl group is a 4- to 6-membered heterocyclic alkyl group. In some embodiments, the heterocyclic alkyl group is a 5- to 6-membered heterocyclic alkyl group. In some embodiments, the heterocyclic alkyl group is a 3- to 8-membered heterocyclic alkenyl group. In some embodiments, the heterocyclic alkyl group is a 3- to 7-membered heterocyclic alkenyl group. In some embodiments, the heterocyclic alkyl group is a 3- to 6-membered heterocyclic alkenyl group. In some embodiments, the heterocyclic alkyl group is a 4- to 6-membered heterocyclic alkenyl group. In some embodiments, the heterocyclic alkyl group is a 5- to 6-membered heterocyclic alkenyl group. Unless otherwise specifically stated in this specification, the heterocyclic alkyl group may optionally be substituted with, for example, oxo, halogen, amino, nitrile, nitro, hydroxy, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, carboxyl, carboxylic acid ester, aryl, cycloalkyl, heterocyclic alkyl, heteroaryl, etc., as described below.In some embodiments, the heterocyclic alkyl group is optionally substituted with an oxo, halogen, methyl, ethyl, -CN, -COOH, COOMe, -CF3, -OH, -OMe, -NH2, or -NO2. In some embodiments, the heterocyclic alkyl group is optionally substituted with a halogen, methyl, ethyl, -CN, -CF3, -OH, or -OMe. In some embodiments, the heterocyclic alkyl group is optionally substituted with a halogen.
[0031] "Heteroaryl" refers to a 5- to 14-membered ring system group comprising one to thirteen carbon atoms, one to six heteroatoms selected from the group consisting of nitrogen, oxygen, phosphorus, and sulfur, and at least one aromatic ring. In some embodiments, the heteroaryl comprises one to three heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur. In some embodiments, the heteroaryl comprises one to three heteroatoms selected from the group consisting of nitrogen and oxygen. In some embodiments, the heteroaryl comprises one to three nitrogen atoms. In some embodiments, the heteroaryl comprises one or two nitrogen atoms. In some embodiments, the heteroaryl comprises one nitrogen atom. The heteroaryl can be a monocyclic, bicyclic, tricyclic, or tetracyclic ring system, which may include a fused ring system (when fused with a cycloalkyl ring or heterocycloalkyl ring, the heteroaryl is bonded by aromatic ring atoms) or a bridged ring system; and the nitrogen, carbon, or sulfur atom in the heteroaryl may optionally be oxidized; the nitrogen atom may optionally be quaternized. In some embodiments, the heteroaryl is a 5- to 10-membered heteroaryl. In some embodiments, the heteroaryl is a 5- to 6-membered heteroaryl. In some embodiments, the heteroaryl group is a 6-membered heteroaryl group. In some embodiments, the heteroaryl group is a 5-membered heteroaryl group. Examples include, but are not limited to, azepinyl, acridine, benzimidazolyl, benzothiazolyl, benzoindolyl, benzodioxacyclopentenyl, benzofuranyl, benzooxazolyl, benzothiazolyl, benzothiadiazolyl, benzo[b][1,4]dioxacycloheptatrienyl, 1,4-benzodioxyl, benzonaphthuryl, benzooxazolyl, benzodioxacyclohexenyl, benzopyranyl, benzopyranoneyl, benzofuranyl, benzofuranoneyl, benzothienyl / benzothiophenyl, benzotriazolyl, benzo[4,6]imidazo[1,2-a]pyridyl, carbazole, cenolinyl, dibenzofuranyl, dibenzothienyl, fur The following groups are listed: nylonyl, furanoneyl, isothiazolyl, imidazolyl, indazole, indolyl, isoindolyl, indololinyl, isoindololinyl, isoquinolinyl, indolazinyl, isoxazolyl, naphridinyl, oxadiazolyl, 2-oxoazapyridine, oxazolyl, ethylene oxide, 1-pyridinyl oxide, 1-pyrimidinyl oxide, 1-pyrazinyl oxide, 1-pyridazinyl oxide, 1-phenyl-1H-pyrroleyl, phenazinyl, phenothiazinyl, phenothiazinyl, phthalazinyl, pteridinyl, purine, pyrroleyl, pyrazolyl, pyridinyl, pyridinyl, pyridinyl, pyrimidinyl, pyridazinyl, quinazolinyl, quinoxalinyl, quininecycloyl, isoquinolinyl, tetrahydroquinolinyl, thiazolyl, thiadiazolyl, triazolyl, tetrazolyl, triazinyl, and thiophenyl (i.e., thienyl). Unless otherwise specified in this specification, heteroaryl groups may optionally be substituted with, for example, halogen, amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, carboxyl, carboxylic acid ester, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, etc.In some embodiments, the heteroaryl group is optionally substituted with a halogen, methyl, ethyl, -CN, -COOH, COOMe, -CF3, -OH, -OMe, -NH2, or -NO2. In some embodiments, the heteroaryl group is optionally substituted with a halogen, methyl, ethyl, -CN, -CF3, -OH, or -OMe. In some embodiments, the heteroaryl group is optionally substituted with a halogen.
[0032] The terms “optional” or “optionally” mean that the event or situation described below may or may not occur, and the description includes both the scenario where said event or situation occurs and the scenario where said event or situation does not occur. For example, “optionally substituted alkyl” means “alkyl” or “substituted alkyl” as defined above. Furthermore, the optionally substituted group can be unsubstituted (e.g., -CH2CH3), fully substituted (e.g., -CF2CF3), monosubstituted (e.g., -CH2CH2F), or substituted at any level between full and monosubstituted (e.g., -CH2CHF2, -CH2CF3, -CF2CH3, -CFHCHF2, etc.). Those skilled in the art will understand that for any group containing one or more substituents, such groups are not intended to introduce any spatially impractical and / or synthetically infeasible substitution or substitution pattern. Therefore, any substituent should generally be understood to have a maximum molecular weight of about 1,000 Daltons, and more typically, at most about 500 Daltons.
[0033] When referring to optional substituents, the term "one or more" means that the subject group is optionally substituted with one, two, three, four, or more substituents. In some embodiments, the subject group is optionally substituted with one, two, three, or four substituents. In some embodiments, the subject group is optionally substituted with one, two, or three substituents. In some embodiments, the subject group is optionally substituted with one or two substituents. In some embodiments, the subject group is optionally substituted with one substituent. In some embodiments, the subject group is optionally substituted with two substituents.
[0034] "Effective dose" or "therapeutic effective dose" refers to the amount of a compound administered to a mammalian subject as a single dose or as part of a series of doses that effectively produces the desired therapeutic effect.
[0035] As used herein, the terms “treat,” “treating,” or “treatment” include relieving, reducing, or improving at least one symptom of a disease or condition, preventing additional symptoms, suppressing a disease or condition, such as preventing the development of a disease or condition, alleviating a disease or condition, causing a disease or condition to subside, relieving a condition caused by a disease or condition, or terminating the symptoms of a disease or condition.
[0036] As used herein, “WRN-related disease or condition”, or alternatively, “WRN-mediated disease or condition”, means any disease or other harmful ailment in which WRN or its mutants are known or suspected to play a role. compound
[0037] This article describes a compound, or a pharmaceutically acceptable salt or stereoisomer thereof, that can be used to treat diseases or conditions associated with WRN.
[0038] This article discloses a compound of formula (I), or a pharmaceutically acceptable salt or stereoisomer thereof: Formula (I), in: X 1 X 2 X 3 X 4 X 5 and X 6 Each of these is independently C, CR, N, O, and S; Z is C(R) Z ) or N; R Z For H, CN, oxo (=O), -NO2, -OH, -OR a -OC(=O)R a -OC(=O)OR b -OC(=O)NR c R d -SF5, -SH, -SR a -S(=O)R a -S(=O)2R a -S(=O)2NR c R d -S(=O)(=NR) b )R b -NR c R d -NR b C(=O)NR c R d -NR b C(=O)R a -NR b C(=O)OR b -NR b S(=O)2R a -N=S(=O)(R b )2、-C(=O)R a -C(=O)OR b-C(=O)NR c R d or -P(=O)(R b )2; R 1 It is a cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkyl, alkenyl, or alkynyl group, wherein each cycloalkyl, heterocycloalkyl, aryl, and heteroaryl group is independently and optionally influenced by one or more R groups. 1a replace; R 2 It is a cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkyl, alkenyl, or alkynyl group, wherein each cycloalkyl, heterocycloalkyl, aryl, and heteroaryl group is independently and optionally influenced by one or more R groups. 2a replace; Ring A is a cycloalkyl or heterocycloalkyl group, wherein the cycloalkyl and heterocycloalkyl groups are independently and optionally separated by one or more R groups. 1A replace; Ring B is a cycloalkyl or heterocycloalkyl group, wherein the cycloalkyl and heterocycloalkyl groups are independently and optionally separated by one or more R groups. 1B replace; The ring C is a cycloalkyl or heterocycloalkyl group, wherein the cycloalkyl and heterocycloalkyl groups are independently and optionally separated by one or more R groups. 1C replace; L is -C(O)-, -S(O)-, -S(O)2- or ; R 5 C 1-6 Alkyl, cycloalkyl, heterocyclic, aryl, or heteroaryl, wherein each alkyl, cycloalkyl, heterocyclic, aryl, and heteroaryl group is independently and optionally influenced by one or more R groups. 5a replace; R 1a R 2a R 1A R 1B R 1C and R 5a Each of these can be independently a halogen, -CN, -NO2, -OH, or -OR. a -OC(=O)R a -OC(=O)OR b -OC(=O)NR c R d -SF5, -SH, -SR a -S(=O)R a -S(=O)2R a -S(=O)2NR c R d -S(=O)(=NR) b )R b -NR cR d -NR b C(=O)NR c R d -NR b C(=O)R a -NR b C(=O)OR b -NR b S(=O)2R a -N=S(=O)(R b )2、-C(=O)R a -C(=O)OR b -C(=O)NR c R d -P(=O)(R b 2. C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is independently and optionally substituted by one or more R; Or two Rs on the same carbon 1a Together they form C2-C6 alkylidene groups that are optionally substituted with one or more R groups; Each R a Independently, it is a C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6 alkylene (cycloalkyl), C1-C6 alkylene (heterocycloalkyl), C1-C6 alkylene (aryl) or C1-C6 alkylene (heteroaryl), wherein each alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is independently and optionally substituted by one or more R; Each R b Independently, it is hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6 alkylene (cycloalkyl), C1-C6 alkylene (heterocycloalkyl), C1-C6 alkylene (aryl) or C1-C6 alkylene (heteroaryl), wherein each alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is independently and optionally substituted by one or more R; R c and R dEach of the following is independently hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6 alkylene (cycloalkyl), C1-C6 alkylene (heterocycloalkyl), C1-C6 alkylene (aryl) or C1-C6 alkylene (heteroaryl), wherein each alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is independently and optionally substituted by one or more R; Or R c and R d Together with the atoms to which they are attached, they form heterocyclic alkyl groups optionally substituted with one or more R atoms; and Each R is independently a halogen, -CN, -OH, -SF5, -SH, -S(=O)C1-C3 alkyl, -S(=O)2C1-C3 alkyl, -S(=O)2NH2, -S(=O)2NHC1-C3 alkyl, -S(=O)2N(C1-C3 alkyl)2, -S(=O)(=NC1-C3 alkyl)(C1-C3 alkyl), -NH2, -NHC1-C3 alkyl, -N(C1-C3 alkyl)2, -N=S(=O)(C1-C3 alkyl) 2. -C(=O)C1-C3 alkyl, -C(=O)OH, -C(=O)OC1-C3 alkyl, -C(=O)NH2, -C(=O)NHC1-C3 alkyl, -C(=O)N(C1-C3 alkyl)2, -P(=O)(C1-C3 alkyl)2, C1-C3 alkyl, C1-C3 alkoxy, C1-C3 haloalkyl, C1-C3 haloalkoxy, C1-C3 hydroxyalkyl, C1-C3 aminoalkyl, C1-C3 heteroalkyl or C3-C6 cycloalkyl; Or two R atoms on the same atom can form an oxo group.
[0039] In some embodiments of the compound of formula (I), It is an aromatic ring. In some embodiments, It is a heterocyclic aromatic ring. In some implementations, It is an aromatic ring. In some embodiments, It is a heterocyclic aromatic ring. In some implementations, It is an aromatic ring. In some embodiments, It is a heterocyclic aromatic ring. In some embodiments, X 2 and X 5 At least one of them is N. In some implementations, X 2 For N and X 5 For C. In some implementations, X 1 For N and X 6 For N. In some implementations, X4 Let N be the number of elements in the array.
[0040] In some embodiments of the compound of formula (I), for , , or In some implementation schemes, It is an aromatic ring. In some embodiments, It is a heterocyclic aromatic ring. In some implementations, It is an aromatic ring. In some embodiments, X 2 and X 5 At least one of them is N. In some implementations, X 1 For N and X 6 Let N be the number of elements in the array.
[0041] In some embodiments of the compound of formula (I), for , , , , , , or .
[0042] In some embodiments of the compound of formula (I), for , , , , , , or .
[0043] In some embodiments of the compound of formula (I), for , , , , or .
[0044] In some embodiments of the compound of formula (I), Selected from , , , , , , , , or .
[0045] In some embodiments of the compound of formula (I), Z is N.
[0046] In some embodiments of the compound of formula (I), Z is C(R) Z In some implementations, R Z For H, CN, oxo (=O), -NO2, -OH, -OR a -OC(=O)R a -OC(=O)OR b -OC(=O)NR c R d -SF5, -SH, -SR a -S(=O)R a -S(=O)2R a -S(=O)2NR c R d -S(=O)(=NR) b )R b -NR c R d -NR b C(=O)NR c R d -NR b C(=O)R a -NR b C(=O)OR b -NR b S(=O)2R a -N=S(=O)(R b )2、-C(=O)R a -C(=O)OR b -C(=O)NR c R d or -P(=O)(R b )2. In some implementation schemes, R Z For H, CN, oxo (=O), -OR a -S(=O)R a -S(=O)2R a -SR a -S(=O)R a -S(=O)2R a -S(=O)2NR c R d -S(=O)(=NR) b )R b -NR c R d -NR b C(=O)NR c Rd -NR b C(=O)R a -NR b C(=O)OR b or -C(=O)R a In some implementations, R Z For H, CN, oxo (=O), -OR a -SR a -S(=O)2R a -S(=O)2NR c R d -NR c R d or -C(=O)NR c R d In some implementations, R Z CN, oxo (=O) or -C (=O)NR c R d In some implementations, R Z Z is CN, oxo(=O), or -C(=O)NH2. In some embodiments, Z is C-CN, C(=O), or CC(=O)NH2. In some embodiments, Z is C(=O).
[0047] In some embodiments of the compound of formula (I), the compound is a compound of formula (Ia): Formula (Ia).
[0048] In some embodiments of compounds of formula (I) or (Ia), ring A is C. 5- C 10 Cycloalkyl or 5- to 10-membered heterocycloalkyl, wherein the cycloalkyl and heterocycloalkyl are independently and optionally constituted by one or more (e.g., two or three, etc.) R 1A Replacement. In some implementations, ring A is C. 5- C 10 cycloalkyl, C 5- C9 cycloalkyl, C 5- C8 cycloalkyl, C 5- C7 cycloalkyl, C 5- C6 cycloalkyl, C5 cycloalkyl, C6 cycloalkyl or C7 cycloalkyl, wherein the cycloalkyl group is independently and optionally surrounded by one or more (e.g., two or three, etc.) R 1AReplacement. In some embodiments, ring A is a 5- to 10-membered heterocyclic alkyl, a 5- to 0-membered heterocyclic alkyl, a 5- to 8-membered heterocyclic alkyl, a 5- to 7-membered heterocyclic alkyl, a 5- to 6-membered heterocyclic alkyl, a 5-membered heterocyclic alkyl, a 6-membered heterocyclic alkyl, or a 7-membered heterocyclic alkyl, wherein the heterocyclic alkyl is optionally and independently replaced by one or more (e.g., two or three, etc.) R 1A Substitution. In some embodiments, the heterocyclic alkyl group comprises one to three heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur. In some embodiments, the heterocyclic alkyl group comprises one or two heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur. In some embodiments, the heterocyclic alkyl group comprises one heteroatom selected from the group consisting of nitrogen and oxygen.
[0049] In some embodiments of compounds of formula (I) or (Ia), each R 1A Independently halogen, -CN, -NO2, -OH, -OR a -SF5, -SH, -SR a -NR c R d The alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl, and heteroaryl groups are C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 5- to 6-membered heterocyclic alkyl, phenyl, or 5- to 6-membered heteroaryl groups; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic alkyl, aryl, and heteroaryl group is independently and optionally substituted by one or more R. In some embodiments, each R is... 1A Independent of halogen, -OH, -OR a -CN, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, or C1-C6 heteroalkyl; wherein each alkyl group is optionally substituted independently by one or more R. In some embodiments, each R 1A Independently, each R is F, Cl, Br, OH, methoxy, ethoxy, propoxy, butoxy, methyl, ethyl, propyl, or butyl. In some embodiments, each R 1A It can be F, OH, or methyl on its own.
[0050] In some embodiments of compounds of formula (I) or (Ia), ring B is C. 4- C 10 Cycloalkyl or 4- to 10-membered heterocycloalkyl, wherein the cycloalkyl and heterocycloalkyl are independently and optionally constituted by one or more (e.g., two or three, etc.) R 1B Replacement. In some implementations, ring B is C. 4- C 10 cycloalkyl, C 5- C 10 cycloalkyl, C 5- C9 cycloalkyl, C5- C8 cycloalkyl, C 5- C7 cycloalkyl, C 5- C6 cycloalkyl, C4 cycloalkyl, C5 cycloalkyl, C6 cycloalkyl or C7 cycloalkyl, wherein the cycloalkyl group is independently and optionally surrounded by one or more (e.g., two or three, etc.) R 1B Replacement. In some embodiments, ring B is a 4- to 10-membered heterocyclic alkyl, 5- to 10-membered heterocyclic alkyl, 5- to 9-membered heterocyclic alkyl, 5- to 8-membered heterocyclic alkyl, 5- to 7-membered heterocyclic alkyl, 5- to 6-membered heterocyclic alkyl, 4- to 8-membered heterocyclic alkyl, 4- to 7-membered heterocyclic alkyl, 4- to 6-membered heterocyclic alkyl, 4-membered heterocyclic alkyl, 5-membered heterocyclic alkyl, 6-membered heterocyclic alkyl, 7-membered heterocyclic alkyl, 8-membered heterocyclic alkyl, wherein the heterocyclic alkyl is optionally and independently replaced by one or more (e.g., two or three, etc.) R 1B Substitution. In some embodiments, the heterocyclic alkyl group comprises one to three heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur. In some embodiments, the heterocyclic alkyl group comprises one or two heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur. In some embodiments, the heterocyclic alkyl group comprises one heteroatomole selected from the group consisting of nitrogen and oxygen. In some embodiments, the heterocyclic alkyl group comprises one nitrogen atom. In some embodiments, ring B is... , , , , , , , , , , , , , , , or Each of them is independently and optionally controlled by one or more (e.g., two or three, etc.) R 1B replace.
[0051] In some embodiments of compounds of formula (I) or (Ia), each R 1B Independently halogen, -CN, -NO2, -OH, -OR a -SF5, -SH, -SR a -NR c R dThe alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl, and heteroaryl groups are C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 5- to 6-membered heterocyclic alkyl, phenyl, or 5- to 6-membered heteroaryl groups; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic alkyl, aryl, and heteroaryl group is independently and optionally substituted by one or more R. In some embodiments, each R is... 1B Independently halogen, -CN, -NO2, -OH, -OR a -SF5, -SH, -SR a -NR c R d C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C3-C6 cycloalkyl, 5- to 6-membered heterocyclic alkyl; wherein each alkyl, cycloalkyl, and heterocyclic alkyl is optionally substituted independently by one or more R. In some embodiments, each R 1B Independently, it is a halogen, a C1-C6 alkyl group, or a C1-C6 haloalkyl group; wherein each alkyl group is optionally substituted by one or more R groups. In some embodiments, each R group is... 1B It can be F, Cl, Br, I, methyl, ethyl, propyl, butyl, -CF3, -CF2H or -CH2CF3.
[0052] In some embodiments of compounds of formula (I) or (Ia), ring B is , , , , , , , , , , or .
[0053] In some embodiments of compounds of formula (I) or (Ia), the ring C is C. 5- C 10 Cycloalkyl or 5- to 10-membered heterocycloalkyl, wherein the cycloalkyl and heterocycloalkyl are independently and optionally constituted by one or more (e.g., two or three, etc.) R 1C Replacement. In some implementations, ring C is C 5- C 10 cycloalkyl, C 5- C9 cycloalkyl, C 5- C8 cycloalkyl, C 5- C7 cycloalkyl, C 5- C6 cycloalkyl, C5 cycloalkyl, C6 cycloalkyl or C7 cycloalkyl, wherein the cycloalkyl group is independently and optionally surrounded by one or more (e.g., two or three, etc.) R1C Replacement. In some embodiments, the ring C is a 5- to 10-membered heterocyclic alkyl, a 5- to 0-membered heterocyclic alkyl, a 5- to 8-membered heterocyclic alkyl, a 5- to 7-membered heterocyclic alkyl, a 5- to 6-membered heterocyclic alkyl, a 5-membered heterocyclic alkyl, a 6-membered heterocyclic alkyl, or a 7-membered heterocyclic alkyl, wherein the heterocyclic alkyl is optionally and independently replaced by one or more (e.g., two or three, etc.) R 1C Substitution. In some embodiments, the heterocyclic alkyl group comprises one to three heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur. In some embodiments, the heterocyclic alkyl group comprises one or two heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur. In some embodiments, the heterocyclic alkyl group comprises one heteroatom selected from the group consisting of nitrogen and oxygen.
[0054] In some embodiments of compounds of formula (I) or (Ia), each R 1C Independently halogen, -CN, -NO2, -OH, -OR a -SF5, -SH, -SR a -NR c R d The alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl, and heteroaryl groups are C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 5- to 6-membered heterocyclic alkyl, phenyl, or 5- to 6-membered heteroaryl groups; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic alkyl, aryl, and heteroaryl group is independently and optionally substituted by one or more R. In some embodiments, each R is... 1C Independently halogen, -CN, -NO2, -OH, -OR a -SF5, -SH, -SR a -NR c R d C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C3-C6 cycloalkyl, 5- to 6-membered heterocyclic alkyl; wherein each alkyl, cycloalkyl, and heterocyclic alkyl is optionally substituted independently by one or more R. In some embodiments, each R 1C Independently, it is a halogen, a C1-C6 alkyl group, or a C1-C6 haloalkyl group; wherein each alkyl group is optionally substituted by one or more R groups. In some embodiments, each R group is... 1C It can be F, Cl, Br, I, methyl, ethyl, propyl, butyl, -CF3, -CF2H or -CH2CF3.
[0055] In some embodiments of the compound of formula (I), the compound is a compound of formula (Iaa): Formula (Iaa) Where n is 0, 1, 2, 3, 4, 5 or 6; m1 is 0, 1, or 2; m2 is 0, 1, or 2; Y 1 For O, S, NR Y1a or CR Y1b R Y1c ; Y 2 For CR Y2 Or N; R Y1a R Y1b R Y1c and R Y2 Each of them is independently hydrogen or R 1A ; Y 3 For bond, O, S, NR Y3a or CR Y3b R Y3c ; Y 4 For CR Y4a R Y4b ; R Y3a R Y3b R Y3c R Y4a and R Y4b Each of them is independently hydrogen or R 1C .
[0056] In some embodiments of the compound of formula (Iaa), n is 0, 1, 2, 3, 4, 5, or 6. In some embodiments, n is 0, 1, 2, 3, or 4. In some embodiments, n is 0, 1, 2, 3, or 4. In some embodiments, n is 0, 1, or 2.
[0057] In some embodiments of the compound of formula (Iaa), m1 is 0, 1, or 2, and m2 is 0, 1, or 2. In some embodiments, m1 is 0, and m2 is 0, 1, or 2. In some embodiments, m1 is 1, and m2 is 0, 1, or 2. In some embodiments, m1 is 1, and m2 is 1. In some embodiments, m1 is 1, and m2 is 0. In some embodiments, m1 is 2, and m2 is 0. In some embodiments, m1 is 0, and m2 is 2.
[0058] In some embodiments of the compound of formula (Iaa), Y 1 For O, S, NR Y1a or CR Y1b R Y1c In some implementation schemes, Y 1 For O, NR Y1a or CRY1b R Y1c In some implementation schemes, Y 2 For CR Y2 Or N.
[0059] In some embodiments of the compound of formula (Iaa), R Y1a R Y1b R Y1c and R Y2 Each of them is independently hydrogen or R 1B In some implementations, R Y1a R Y1b R Y1c and R Y2 Each of these can be independently hydrogen, halogen, -CN, -NO2, -OH, or -OR. a -SF5, -SH, -SR a -NR c R d C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C3-C6 cycloalkyl, 5- to 6-membered heterocyclic alkyl; wherein each alkyl, cycloalkyl, and heterocyclic alkyl is optionally substituted independently by one or more R. In some embodiments, R Y1a R Y1b R Y1c and R Y2 Each of these is independently hydrogen, halogen, C1-C6 alkyl, or C1-C6 haloalkyl; wherein each alkyl group is optionally substituted by one or more R. In some embodiments, R Y1a R Y1b R Y1c and R Y2 Each of these is hydrogen, F, Cl, Br, I, methyl, ethyl, propyl, butyl, -CF3, -CF2H, or -CH2CF3. In some embodiments, R Y1a R Y1b R Y1c and R Y2 Each of them is either hydrogen or methyl.
[0060] In some embodiments of the compound of formula (Iaa), Y 3 For bond, O, S, NR Y3a or CR Y3b R Y3c In some implementation schemes, Y 3 For bond, O or CR Y3b R Y3c In some implementation schemes, Y 3 As the key. In some implementations, Y 3 For O. In some implementations, Y3 For CR Y3b R Y3c In some implementation schemes, Y 4 For CR Y4a R Y4b .
[0061] In some embodiments of the compound of formula (Iaa), R Y3a R Y3b R Y3c R Y4a and R Y4b Each of these can be independently hydrogen, halogen, -CN, -NO2, -OH, or -OR. a -SF5, -SH, -SR a -NR c R d C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C3-C6 cycloalkyl, 5- to 6-membered heterocyclic alkyl; wherein each alkyl, cycloalkyl, and heterocyclic alkyl is optionally substituted independently by one or more R. In some embodiments, R Y3a R Y3b R Y3c R Y4a and R Y4b Each of these is independently hydrogen, halogen, C1-C6 alkyl, or C1-C6 haloalkyl; wherein each alkyl group is optionally substituted by one or more R. In some embodiments, R Y3a R Y3b R Y3c R Y4a and R Y4b Each of these can be hydrogen, F, Cl, Br, I, methyl, ethyl, propyl, butyl, -CF3, -CF2H, or -CH2CF3.
[0062] In some embodiments of compounds of formula (I), (Ia), or (Iaa), X 1 It is either -N- or -CH-. In some implementations, X 1 For -N-. In some implementations, X 1 It is -CH-.
[0063] In some embodiments of compounds of formula (I), (Ia), or (Iaa), R 1 For C3-C 12 Cycloalkyl, 3- to 12-membered heterocycloalkyl, C 6-12 Aryl, 5 to 12-membered heteroaryl, C1-C6 alkyl, C2-C6 alkenyl or C2-C6 ynyl, wherein each cycloalkyl, heterocycloalkyl, aryl and heteroaryl group is independently and optionally bound by one or more (e.g., two or three, etc.) R 1aReplacement. In some implementations, R 1 For C3-C 12 cycloalkyl, C3-C 10 Cycloalkyl, C3-C8 cycloalkyl, C3-C6 cycloalkyl, C5-C6 cycloalkyl, C4 cycloalkyl, C5 cycloalkyl, C6 cycloalkyl, C7 cycloalkyl, or C8 cycloalkyl, wherein each cycloalkyl group is independently and optionally surrounded by one or more (e.g., two or three, etc.) R 1a Replacement. In some implementations, R 1 It is a 3- to 12-membered heterocyclic alkyl, a 3- to 10-membered heterocyclic alkyl, a 3- to 8-membered heterocyclic alkyl, a 3- to 7-membered heterocyclic alkyl, a 3- to 6-membered heterocyclic alkyl, a 4- to 6-membered heterocyclic alkyl, a 5- to 6-membered heterocyclic alkyl, a 3-membered heterocyclic alkyl, a 4-membered heterocyclic alkyl, a 5-membered heterocyclic alkyl, a 6-membered heterocyclic alkyl, or a 7-membered heterocyclic alkyl, wherein each heterocyclic alkyl is independently and optionally surrounded by one or more (e.g., two or three, etc.) R 1a Replacement. In some implementations, R 1 C 6-12 Aryl, C 6-10 Aryl or phenyl, wherein each aryl or phenyl group is independently and optionally influenced by one or more (e.g., two or three, etc.) R 1a Replacement. In some implementations, R 1 The heteroaryl group is 5 to 12-membered, 5 to 10-membered, 5 to 9-membered, 5 to 8-membered, 5-membered, 6-membered, 8-membered, 9-membered, or 10-membered, wherein each heteroaryl group is independently and optionally surrounded by one or more (e.g., two or three, etc.) R 1a replace.
[0064] In some embodiments of compounds of formula (I), (Ia), or (Iaa), each R 1a Independently halogen, -CN, -NO2, -OH, -OR a -OC(=O)R a -OC(=O)OR b -OC(=O)NR c R d -SF5, -SH, -SR a -S(=O)R a -S(=O)2R a -S(=O)2NR c R d -S(=O)(=NR) b )R b -NR c R d -NR b C(=O)NR c R d-NR b C(=O)R a -NR b C(=O)OR b -NR b S(=O)2R a -N=S(=O)(R b )2、-C(=O)R a -C(=O)OR b -C(=O)NR c R d -P(=O)(R b 2. C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 3- to 6-membered heterocyclic alkyl, C 6-10 Aryl or 5- to 6-membered heteroaryl; wherein each alkyl, alkenyl, ynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl group is independently and optionally substituted by one or more R. In some embodiments, each R 1a Independent of halogen, -OR a -SF5, -SR a C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C3-C6 cycloalkyl, or 3- to 6-membered heterocyclic alkyl, wherein each alkyl, cycloalkyl, and heterocyclic alkyl is optionally substituted independently by one or more R. In some embodiments, each R 1a Independently, it can be F, Cl, Br, I, CH3, CH2CH3, CF3, CF2H, CF2CF3, CH2CF3, SCF3, OCH3, OCH2CH3, OC2F5, OCF2Cl, SF5. , or In some implementations, two R atoms on the same carbon atom... 1a Together they form a C2-C6 alkylidene group optionally substituted with one or more R groups. In some embodiments, two R groups on the same carbon atom... 1a Together they form a C2-C3 alkylidene group optionally substituted with one or more R groups. In some embodiments, two R groups on the same carbon atom... 1a Together they form = CF2.
[0065] In some embodiments of compounds of formula (I), (Ia), or (Iaa), R 1 for , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , or .
[0066] In some embodiments of compounds of formula (I), (Ia), or (Iaa), R 2 For C3-C 12 Cycloalkyl, 3- to 12-membered heterocycloalkyl, C 6-12 Aryl, 5 to 12-membered heteroaryl, C1-C6 alkyl, C2-C6 alkenyl or C2-C6 ynyl, wherein each cycloalkyl, heterocycloalkyl, aryl and heteroaryl group is independently and optionally bound by one or more (e.g., two or three, etc.) R 2a Replacement. In some implementations, R 2 For C3-C 12 cycloalkyl, C3-C 10 Cycloalkyl, C3-C8 cycloalkyl, C3-C6 cycloalkyl, C5-C6 cycloalkyl, C4 cycloalkyl, C5 cycloalkyl, C6 cycloalkyl, C7 cycloalkyl, or C8 cycloalkyl, wherein each cycloalkyl group is independently and optionally surrounded by one or more (e.g., two or three, etc.) R 2a Replacement. In some implementations, R 2It is a 3- to 12-membered heterocyclic alkyl, a 3- to 10-membered heterocyclic alkyl, a 3- to 8-membered heterocyclic alkyl, a 3- to 7-membered heterocyclic alkyl, a 3- to 6-membered heterocyclic alkyl, a 4- to 6-membered heterocyclic alkyl, a 5- to 6-membered heterocyclic alkyl, a 3-membered heterocyclic alkyl, a 4-membered heterocyclic alkyl, a 5-membered heterocyclic alkyl, a 6-membered heterocyclic alkyl, or a 7-membered heterocyclic alkyl, wherein each heterocyclic alkyl is independently and optionally surrounded by one or more (e.g., two or three, etc.) R 2a Replacement. In some implementations, R 2 C 6-12 Aryl, C 6-10 Aryl or phenyl, wherein each aryl or phenyl group is independently and optionally influenced by one or more (e.g., two or three, etc.) R 2a Replacement. In some implementations, R 2 The heteroaryl group is 5 to 12-membered, 5 to 10-membered, 5 to 9-membered, 5 to 8-membered, 5-membered, 6-membered, 8-membered, 9-membered, or 10-membered, wherein each heteroaryl group is independently and optionally surrounded by one or more (e.g., two or three, etc.) R 2a replace.
[0067] In some embodiments of compounds of formula (I), (Ia), or (Iaa), R 2 for , , , , , , , , , , , , , , , , or Each of them is independently and optionally controlled by one or more (e.g., two or three, etc.) R 2a replace.
[0068] In some embodiments of compounds of formula (I), (Ia), or (Iaa), each R 2a Independently halogen, -CN, -NO2, -OH, -OR a -OC(=O)R a -OC(=O)OR b -OC(=O)NR c R d -SF5, -SH, -SR a -S(=O)R a -S(=O)2Ra -S(=O)2NR c R d -S(=O)(=NR) b )R b -NR c R d -NR b C(=O)NR c R d -NR b C(=O)R a -NR b C(=O)OR b -NR b S(=O)2R a -N=S(=O)(R b )2、-C(=O)R a -C(=O)OR b -C(=O)NR c R d -P(=O)(R b 2. C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 3- to 6-membered heterocyclic alkyl, C 6-10 Aryl or 5- to 6-membered heteroaryl; wherein each alkyl, alkenyl, ynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl group is independently and optionally substituted by one or more R. In some embodiments, each R 2a Independent of halogen, -OR a -SF5, -SR a C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C3-C6 cycloalkyl, or 3- to 6-membered heterocyclic alkyl, wherein each alkyl, cycloalkyl, and heterocyclic alkyl is optionally substituted independently by one or more R. In some embodiments, each R 2a Independently, it can be F, Cl, Br, I, CH3, CH2CH3, CF3, CF2H, CF2CF3, CH2CF3, SCF3, OCH3, OCH2CH3, OC2F5, OCF2Cl, SF5. , or .
[0069] In some embodiments of compounds of formula (I), (Ia), or (Iaa), R 2 for , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , or .
[0070] In some embodiments of compounds of formula (I), (Ia), or (Iaa), L is -C(O)-, -S(O)-, -S(O)2-, and In some implementations, L is -C(O)-. In some implementations, L is -S(O)-. In some implementations, L is -S(O)2-. In some implementations, L is... .
[0071] In some embodiments of compounds of formula (I), (Ia), or (Iaa), R 5 C 1-6 Alkyl, C 3-12 Cycloalkyl, 3 to 12-membered heterocyclic groups, C 6-12 aryl or 5 to 12-membered heteroaryl, wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl group is independently and optionally bounded by one or more R 5a Replacement. In some implementations, R 5 C 1-3 Alkyl, C 1-4 Alkyl, C 1-6 Alkyl, C1 alkyl, C2 alkyl, C3 alkyl, C4 alkyl, C5 alkyl or C -6 Alkyl groups, wherein each alkyl group is independently and optionally bound by one or more R groups. 5a Replacement. In some implementations, R 5 C 3-12 cycloalkyl, C 3-10 cycloalkyl, C 3-9 cycloalkyl, C 3-8 cycloalkyl, C 3-7 cycloalkyl, C3-6 cycloalkyl, C 4-8 cycloalkyl, C 5-6 Cycloalkyl, C3 cycloalkyl, C4 cycloalkyl, C5 cycloalkyl, C6 cycloalkyl, C7 cycloalkyl, C8 cycloalkyl or C9 cycloalkyl, wherein each cycloalkyl group is independently and optionally influenced by one or more R groups. 5a Replacement. In some implementations, R 5 It is a 3- to 12-membered heterocyclic alkyl, a 3- to 10-membered heterocyclic alkyl, a 3- to 9-membered heterocyclic alkyl, a 3- to 8-membered heterocyclic alkyl, a 4- to 9-membered heterocyclic alkyl, a 5- to 9-membered heterocyclic alkyl, a 5- to 6-membered heterocyclic alkyl, a 6- to 9-membered heterocyclic alkyl, a 3- to 9-membered heterocyclic alkyl, a 4-membered heterocyclic alkyl, a 5-membered heterocyclic alkyl, a 6-membered heterocyclic alkyl, a 7-membered heterocyclic alkyl, an 8-membered heterocyclic alkyl, or a 9-membered heterocyclic alkyl, wherein each heterocyclic alkyl is optionally independently bound by one or more R 5a Replacement. In some implementations, R 5 C 6-12 Aryl, C 6-10 Aryl or C6 aryl, wherein each aryl group is independently and optionally bounded by one or more R 5a Replacement. In some implementations, R 5 The heteroaryl group is 5 to 12-membered, 5 to 11-membered, 5 to 10-membered, 5 to 9-membered, 6 to 10-membered, 6 to 9-membered, 5 to 6-membered, 5-membered, 6-membered, 7-membered, 8-membered, 9-membered, 10-membered, 11-membered, or 12-membered, wherein each heteroaryl group is independently and optionally bonded by one or more R groups. 5a replace.
[0072] In some embodiments of compounds of formula (I), (Ia), or (Iaa), R 5 for , , , , , , , , , , , , , , , , , ,or Each of them is independently and optionally controlled by one or more R 5a replace.
[0073] In some embodiments of compounds of formula (I), (Ia), or (Iaa), each R 5a Independently halogen, -CN, -NO2, -OH, -OR a -OC(=O)R a -OC(=O)OR b -OC(=O)NR c R d -SF5, -SH, -SR a -S(=O)R a -S(=O)2R a -S(=O)2NR c R d -S(=O)(=NR) b )R b -NR c R d -NR b C(=O)NR c R d -NR b C(=O)R a -NR b C(=O)OR b -NR b S(=O)2R a -N=S(=O)(R b )2、-C(=O)R a -C(=O)OR b -C(=O)NR c R d -P(=O)(R b 2. C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl group is independently and optionally substituted by one or more R. In some embodiments, halogen, -CN, -OH, -OR a C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C2-C6 alkenyl, C2-C6 ynyl, C3-C6 cycloalkyl, 3- to 6-membered heterocyclic alkyl, C 6-10 Aryl or 5- to 6-membered heteroaryl; wherein each alkyl, alkenyl, ynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl group is independently and optionally substituted by one or more R.
[0074] In some embodiments of compounds of formula (I), (Ia), or (Iaa), R 5 for , , , , , , , , , , , , , , , , , , , , , , or .
[0075] In some embodiments of compounds of formula (I), (Ia), or (Iaa), LR 5 for , , , , , , , , , , , or Each of them is independently and optionally controlled by one or more R 5a replace.
[0076] In some embodiments of compounds of formula (V), (II), (IIa), (I), (Ia), or (Iaa), LR 5 for , , , , , , , , , , , , , , , , , , , , , , , , , , , or .
[0077] In some embodiments of the compounds disclosed herein, each R a Independently, each alkyl, alkylene, cycloalkyl, and heterocycloalkyl group is a C1-C6 alkyl group, a C1-C6 haloalkyl group, a C1-C6 hydroxyalkyl group, a C1-C6 aminoalkyl group, a C1-C6 heteroalkyl group, a cycloalkyl group, a heterocycloalkyl group, a C1-C6 alkylene group (cycloalkyl), or a C1-C6 alkylene group (heterocycloalkyl), wherein each alkyl, alkylene, cycloalkyl, and heterocycloalkyl group is optionally substituted by one or more R. In some embodiments of the compounds disclosed herein, each R... a The alkyl group is independently a C1-C6 alkyl, C1-C6 haloalkyl, cycloalkyl, or heterocycloalkyl group, wherein each alkyl, cycloalkyl, and heterocycloalkyl group is optionally substituted by one or more R. In some embodiments of the compounds disclosed herein, each R a The alkyl group is independently a C1-C6 alkyl, C1-C6 haloalkyl, cycloalkyl, or heterocycloalkyl group, wherein each alkyl, cycloalkyl, and heterocycloalkyl group is optionally substituted by one or more R. In some embodiments of the compounds disclosed herein, each R a Each alkyl group is independently a C1-C6 alkyl or C1-C6 haloalkyl group, wherein each alkyl group is optionally substituted by one or more R groups. In some embodiments of the compounds disclosed herein, each R group is... a The compounds are independently cycloalkyl or heterocycloalkyl, wherein each cycloalkyl and heterocycloalkyl group is optionally substituted by one or more R groups. In some embodiments of the compounds disclosed herein, each R group is... a Independently, each R is a C1-C6 alkyl or C1-C6 haloalkyl. In some embodiments of the compounds disclosed herein, each R a It is independently a C1-C6 alkyl group.
[0078] In some embodiments of the compounds disclosed herein, each R b Independently, it is hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, cycloalkyl, heterocycloalkyl, C1-C6 alkylene (cycloalkyl), or C1-C6 alkylene (heterocycloalkyl), wherein each alkyl, alkylene, cycloalkyl, and heterocycloalkyl is optionally substituted by one or more R. In some embodiments of the compounds disclosed herein, each R bIndependently, it is hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, cycloalkyl, or heterocycloalkyl, wherein each alkyl, cycloalkyl, and heterocycloalkyl is optionally substituted by one or more R. In some embodiments of the compounds disclosed herein, each R b Independently, it is hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, cycloalkyl, or heterocycloalkyl, wherein each alkyl, cycloalkyl, and heterocycloalkyl is optionally substituted by one or more R. In some embodiments of the compounds disclosed herein, each R b Independently hydrogen, C1-C6 alkyl, or C1-C6 haloalkyl, wherein each alkyl group is optionally substituted by one or more R. In some embodiments of the compounds disclosed herein, each R b Independently hydrogen, cycloalkyl, or heterocycloalkyl, wherein each cycloalkyl and heterocycloalkyl group is optionally substituted by one or more R. In some embodiments of the compounds disclosed herein, each R b Independently, it is hydrogen, C1-C6 alkyl, or C1-C6 haloalkyl. In some embodiments of the compounds disclosed herein, each R... b Independently hydrogen or C1-C6 alkyl. In some embodiments of the compounds disclosed herein, each R... b It is hydrogen. In some embodiments of the compounds disclosed herein, each R... b It is independently a C1-C6 alkyl group.
[0079] In some embodiments of the compounds disclosed herein, R c and R d Each of the following is independently hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, cycloalkyl, heterocycloalkyl, C1-C6 alkylene (cycloalkyl), or C1-C6 alkylene (heterocycloalkyl), wherein each alkyl, alkylene, cycloalkyl, and heterocycloalkyl is optionally substituted by one or more R. In some embodiments of the compounds disclosed herein, R c and R d Each is independently hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, cycloalkyl, or heterocycloalkyl, wherein each alkyl, cycloalkyl, and heterocycloalkyl is optionally substituted by one or more R. In some embodiments of the compounds disclosed herein, R c and R d Each is independently hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, cycloalkyl, or heterocycloalkyl, wherein each alkyl, cycloalkyl, and heterocycloalkyl is optionally substituted by one or more R. In some embodiments of the compounds disclosed herein, R c and R dEach is independently hydrogen, a C1-C6 alkyl group, or a C1-C6 haloalkyl group, wherein each alkyl group is optionally substituted by one or more R groups. In some embodiments of the compounds disclosed herein, R groups are... c and R d Each is independently hydrogen, cycloalkyl, or heterocycloalkyl, wherein each cycloalkyl and heterocycloalkyl group is optionally substituted by one or more R. In some embodiments of the compounds disclosed herein, R c and R d Each is independently hydrogen, C1-C6 alkyl, or C1-C6 haloalkyl. In some embodiments of the compounds disclosed herein, R c and R d Each is independently hydrogen or C1-C6 alkyl. In some embodiments of the compounds disclosed herein, R c and R d Each is hydrogen. In some embodiments of the compounds disclosed herein, R c and R d Each is independently a C1-C6 alkyl group.
[0080] In some embodiments of the compounds disclosed herein, R c and R d Together with the atoms to which they are attached, they form heterocyclic alkyl groups that are optionally substituted with one or more R atoms.
[0081] In some embodiments of the compounds disclosed herein, each R is independently a halogen, -CN, -OH, -NH2, -NHC1-C3 alkyl, -N(C1-C3 alkyl)2, -C(=O)C1-C3 alkyl, -C(=O)OH, -C(=O)OC1-C3 alkyl, -C(=O)NH2, -C(=O)NHC1-C3 alkyl, -C(=O)N(C1-C3 alkyl)2, C1-C3 alkyl, C1-C3 alkoxy, C1-C3 haloalkyl, C1-C3 haloalkoxy, C1-C3 hydroxyalkyl, C1-C3 aminoalkyl, C1-C3 heteroalkyl, or C3-C6 cycloalkyl; or two Rs on the same atom form an oxo group. In some embodiments of the compounds disclosed herein, each R is independently a halogen, -CN, -OH, -NH2, -NHC1-C3 alkyl, -N(C1-C3 alkyl)2, -C(=O)C1-C3 alkyl, C1-C3 alkyl, C1-C3 alkoxy, C1-C3 haloalkyl, C1-C3 haloalkoxy, C1-C3 hydroxyalkyl, C1-C3 aminoalkyl, C1-C3 heteroalkyl, or C3-C6 cycloalkyl; or two Rs on the same atom form an oxo group. In some embodiments of the compounds disclosed herein, each R is independently a halogen, -CN, -OH, -NH2, C1-C3 alkyl, C1-C3 alkoxy, C1-C3 haloalkyl, C1-C3 haloalkoxy, C1-C3 hydroxyalkyl, C1-C3 aminoalkyl, C1-C3 heteroalkyl, or C3-C6 cycloalkyl; or two Rs on the same atom form an oxo group. In some embodiments of the compounds disclosed herein, each R is independently a halogen, -CN, -OH, -NH2, C1-C3 alkyl, C1-C3 alkoxy, or C1-C3 haloalkyl; or two Rs on the same atom form an oxo group.
[0082] In some embodiments of the compounds disclosed herein, R, R 1 R 1a R 2 R 2a R 3 R 4 R 5 R 6 R 7 R 2a R 1A R 1B R 1C R 5a R a R b R c RY1a R Y1b R Y1c R Y2 R Y3a R Y3b R Y3c R Y4a R Y4b and R d One or more of the groups contain deuterium, and the percentage is higher than the natural abundance of deuterium.
[0083] In some embodiments of the compounds disclosed herein, the following groups R, R 1 R 1a R 2 R 2a R 3 R 4 R 5 R 6 R 7 R 2a R 1A R 1B R 1C R 5a R a R b R c R Y1a R Y1b R Y1c R Y2 R Y3a R Y3b R Y3c R Y4a R Y4b and R d One or more of them, one or more of them 1 H is replaced by one or more deuterium atoms.
[0084] In some embodiments of the compounds disclosed herein, R, R 1 R 1a R 2 R 2a R 3 R 4 R 5 R 6 R 7 R 2a R 1A R 1B R 1C R 5a R a R b R c R Y1a R Y1b RY1c R Y2 R Y3a R Y3b R Y3c R Y4a R Y4b and R d The abundance of each intermediate deuterium in the molar is independently calculated as at least 1%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or 100%.
[0085] In some embodiments of the compounds disclosed herein, one or more of ring A, ring B, or ring C 1 H is replaced by one or more deuterium atoms.
[0086] This document considers any combination of the aforementioned groups for each variable. Throughout the specification, the groups and their substituents were selected by those skilled in the art to provide stable moieties and compounds.
[0087] In some embodiments, the compounds disclosed herein, or their pharmaceutically acceptable salts or stereoisomers, are one of the compounds listed in Table 1. Table 1
[0088] In some embodiments, the compounds disclosed herein, or their pharmaceutically acceptable salts or stereoisomers, are one of the compounds listed in Table 2. Table 2 Other forms of the compounds disclosed herein Isomers / stereoisomers
[0089] In some embodiments, the compounds described herein exist as geometric isomers. In some embodiments, the compounds described herein have one or more double bonds. The compounds presented herein include all cis, trans, syn, anti, E-type (E), and Z-type (Zusammen, Z) isomers, and corresponding mixtures thereof. In some cases, the compounds described herein have one or more chiral centers, each center existing in an R or S configuration. The compounds described herein include all diastereomeric, enantiomeric, and epimeric forms, and corresponding mixtures thereof. In further embodiments of the compounds and methods provided herein, mixtures of enantiomers and / or diastereomeric compounds produced by a single preparation step, combination, or tautomerization can be used for the applications described herein. In some embodiments, the compounds described herein are prepared as separate stereoisomers by reacting a racemic mixture of the compounds with an optically active resolving agent to form a pair of diastereomeric compounds, separating the diastereomeric compounds, and recovering the optically pure enantiomers. In some embodiments, dissociable complexes are preferred. In some embodiments, diastereomers possess different physical properties (e.g., melting point, boiling point, solubility, reactivity, etc.) and are separated by utilizing these differences. In some embodiments, diastereomers are separated by chiral chromatography, or preferably by a separation / resolution technique based on solubility differences. In some embodiments, the optically pure enantiomers, along with the resolving agent, are then recovered by any practical means that does not lead to racemization.
[0090] Unless otherwise stated, in this disclosure, the solid wedge ( ) and virtual wedge line ( The bond, represented by a solid line, is used to indicate the absolute configuration of the chiral center. ) and dashed lines ( The bond, represented by ) is used to indicate the relative configuration of the chiral center, and is indicated by wavy lines ( The key indicated by ) is used to indicate (1) solid wedge ( ) or virtual wedge line ( (), or (2) solid line ( ) or dashed line ( ). Isotope enrichment compounds
[0091] Unless otherwise specified, the compounds described herein may exhibit their natural isotopic abundance, or one or more of the atoms may be artificially enriched with a specific isotope that has the same atomic number but an atomic mass or mass number different from the atomic mass or mass number predominantly found in nature. All isotopic variants of the compounds of the present disclosure, whether radioactive or not, are encompassed within the scope of the present disclosure. For example, hydrogen has three naturally occurring isotopes, denoted as 1 H (protium), 2 H (deuterium) and 3 H (tritium). Protium is the most abundant isotope of hydrogen in nature. Enrichment with deuterium may provide certain therapeutic advantages, such as increased in vivo half-life and / or exposure, or may provide compounds that can be used to study in vivo pathways of drug elimination and metabolism.
[0092] For example, the compounds described herein may be artificially enriched with one or more specific isotopes. In some embodiments, the compounds described herein may be artificially enriched with one or more isotopes that are not predominantly present in nature. In some embodiments, the compounds described herein may be artificially enriched with one or more isotopes selected from deuterium ( 2 H), tritium ( 3 H), iodine-125 ( 125 I) or carbon-14 ( 14 C). In some embodiments, the compounds described herein are artificially enriched with one or more selected from 2 H, 11 C, 13 C, 14 C, 15 C, 12 N, 13 N, 15 N, 16 N, 16 O, 17 O, 14 F, 15 F, 16 F, 17 F, 18 F, 33 S, 34 S, 35 S, 36 S, 35 Cl, 37 Cl, 79 Br, 81 Br, 131 I and 125Isotopes of I. In some embodiments, the abundance of the enriched isotopes is independently at least 1%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or 100% in molar.
[0093] In some embodiments, the compound is deuterated at at least one position. In some embodiments, some or all of the compounds disclosed herein... 1 H atoms are 2 H atom substitution.
[0094] Methods for synthesizing deuterium-containing compounds are known in the art, and are included only by non-limiting example the procedures described in U.S. Patent Nos. 5,846,514 and 6,334,997, as well as the synthetic methods described below. For example, deuterium-substituted compounds can be synthesized using a variety of methods, as described below: Dean, Dennis C.; editor. Recent Advances in the Synthesis and Applications of Radiolabeled Compounds for Drug Discovery and Development. [See: Curr., Pharm.Des., 2000; 6(10)] 2000, 110 pp; George W.; Varma, Rajender S. The Synthesis of Radiolabeled Compounds via Organometallic Intermediates, Tetrahedron, 1989, 45(21), 6601-21; and Evans, E. Anthony. Synthesis of radiolabeled compounds, J. Radioanal.Chem., 1981, 64(1-2), 9-32.
[0095] Deuterated starting materials are readily available and can be synthesized using the methods described herein to provide the synthesis of deuterium-containing compounds. A wide range of deuterium-containing reagents and building blocks are commercially available from chemical suppliers such as Aldrich Chemical Co. Pharmaceutically acceptable salts
[0096] In some embodiments, the compounds described herein are present as pharmaceutically acceptable salts. In some embodiments, the methods disclosed herein include methods of treating a disease by administering such pharmaceutically acceptable salts. In some embodiments, the methods disclosed herein include methods of treating a disease by administering such pharmaceutically acceptable salts as a pharmaceutical composition.
[0097] In some embodiments, the compounds described herein have acidic or basic groups and thus react with a variety of inorganic or organic bases and any of inorganic and organic acids to form pharmaceutically acceptable salts. In some embodiments, these salts are prepared in situ during the final isolation and purification of the compounds disclosed herein or their stereoisomers, or by reacting the purified compounds in their free form with a suitable acid or base alone and isolating the resulting salts.
[0098] Examples of pharmaceutically acceptable salts include those prepared by reacting the compounds described herein with minerals, organic acids, or inorganic bases. These salts include: acetates, acrylates, adipates, alginates, aspartates, benzoates, benzenesulfonates, bisulfates, bisulfites, bromides, butyrates, butyn-1,4-dicitates, camphorates, camphorsulfonates, hexanoates, octanoates, chlorobenzoates, chlorides, citrates, cyclopentanepropionates, decanoates, disglucurons, dihydrogen phosphates, dinitrobenzoates, dodecyl sulfates, ethanesulfonates, formates, fumarates, glucono-2-phosphates, glycerophosphates, glycolates, hemisulfates, heptahydrates, hexyn-1,6-dicitates, hydroxybenzoates, and gamma-hydroxybutyrates. Salts, hydrochlorides, hydrobromides, hydroiodates, 2-hydroxyethanesulfonates, iodides, isobutyrates, lactates, maleates, malonates, methanesulfonates, mandelates, metaphosphates, methanesulfonates, methoxybenzoates, methylbenzoates, hydrogen phosphates, 1-naphthalenesulfonates, 2-naphthalenesulfonates, nicotinates, nitrates, palmitates, pectinates, persulfates, 3-phenylpropionates, phosphates, picrates, neopentanoates, propionates, pyrosulfates, pyrophosphates, propynates, phthalates, phenylacetates, phenylbutyrates, propanesulfonates, salicylates, succinates, sulfates, sulfites, succinates, octanoates, sebacic acid salts, sulfonates, tartrates, thiocyanates, toluenesulfonates, undecanoates, and xylenesulfonates.
[0099] Furthermore, the compounds described herein can be prepared as pharmaceutically acceptable salts, which are formed by reacting the free base form of the compounds with pharmaceutically acceptable inorganic or organic acids, including but not limited to inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, metaphosphoric acid, etc.; and organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, p-toluenesulfonic acid, tartaric acid, trifluoroacetic acid, citric acid, benzoic acid, etc. Acids, including 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, arylsulfonic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 2-naphthalenesulfonic acid, 4-methylbicyclo-[2.2.2]oct-2-en-1-carboxylic acid, glucoheponic acid, 4,4'-methylenebis-(3-hydroxy-2-en-1-carboxylic acid), 3-phenylpropionic acid, trimethylacetic acid, tert-butylacetic acid, dodecyl sulfate, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, and mucoconic acid. In some embodiments, other acids, such as oxalic acid, although not pharmaceutically acceptable on their own, are used to prepare salts that can be used as intermediates in obtaining the compounds disclosed herein or their stereoisomers and their pharmaceutically acceptable acid addition salts.
[0100] In some embodiments, the compounds described herein containing free acid groups react with suitable bases (such as hydroxides, carbonates, bicarbonates, and sulfates of pharmaceutically acceptable metal cations), with ammonia, or with pharmaceutically acceptable primary, secondary, tertiary, or quaternary organic amines. Representative salts include alkali metal or alkaline earth metal salts, such as lithium, sodium, potassium, calcium, and magnesium salts, as well as aluminum salts. Illustrative examples of bases include sodium hydroxide, potassium hydroxide, choline hydroxide, sodium carbonate, and N2SO4. + (C 1-4 Alkyl)4, etc.
[0101] Representative organic amines that can be used to form base addition salts include ethylamine, diethylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine, etc. It should be understood that the compounds described herein also include quaternization of any basic nitrogen-containing groups they contain. In some embodiments, water-soluble or oil-soluble or dispersible products are obtained via such quaternization. tautomer
[0102] In some cases, compounds exist as tautomers. The compounds described herein include all possible tautomers within the formulas described herein. Tautomers are compounds that can interconvert through hydrogen atom migration accompanied by the conversion of single bonds with adjacent double bonds. In the possible tautomer bond arrangements, there will be a chemical equilibrium of tautomers. All tautomer forms of the compounds disclosed herein are considered. The precise ratio of tautomers depends on several factors, including temperature, solvent, and pH. Treatment
[0103] This article discloses methods for modulating WRN activity in subjects, including administering the compound described herein, or a pharmaceutically acceptable salt or stereoisomer thereof, to the subject.
[0104] On the other hand, this article provides methods for inhibiting WRN activity in subjects, including administering the compound described herein, or a pharmaceutically acceptable salt or stereoisomer thereof, to the subject.
[0105] In some implementations, the disease or condition is cancer.
[0106] In some embodiments, the cancer is a solid tumor. In some embodiments, the cancer is characterized by microsatellite high instability (MSI-H) or mismatch repair deficiency (dMMR). In some embodiments, cancers characterized by microsatellite high instability (MSI-H) or mismatch repair deficiency (dMMR) are selected from colorectal cancer, gastric cancer, prostate cancer, and endometrial cancer. In some embodiments, cancers characterized by microsatellite high instability (MSI-H) or mismatch repair deficiency (dMMR) are selected from uterine endometrial cancer, colonic adenocarcinoma, gastric adenocarcinoma, rectal adenocarcinoma, adrenocortical carcinoma, uterine carcinosarcoma, cervical squamous cell carcinoma, cervical endometrial adenocarcinoma, esophageal cancer, breast cancer, renal clear cell carcinoma, prostate cancer, and ovarian serous cystadenocarcinoma. Dosage
[0107] In some embodiments, a composition containing the compounds described herein is administered for therapeutic treatment. In some therapeutic applications, the composition is administered to a patient with a disease or ailment in an amount sufficient to cure or at least partially suppress at least one symptom of the disease or ailment. The effective amount for this purpose depends on the severity and course of the disease or ailment, prior treatment, the patient's health status, weight, and response to the drug, as well as the judgment of the attending physician. The therapeutically effective amount may optionally be determined by methods including, but not limited to, dose escalation and / or dose range clinical trials. Application route
[0108] Suitable routes of administration include, but are not limited to, oral, intravenous, rectal, aerosol, parenteral, ocular, pulmonary, transmucosal, transdermal, vaginal, ear, nasal, and topical administration. Furthermore, by way of example only, parenteral delivery includes intramuscular, subcutaneous, intravenous, intramedullary injection, as well as intrathecal, direct intraventricular, intraperitoneal, intralymphatic, and intranasal injection. Pharmaceutical Compositions / Formulations
[0109] In accordance with standard pharmaceutical practice, the compounds described herein are administered, in the form of a pharmaceutical composition, alone or in combination with a pharmaceutically acceptable carrier, excipient, or diluent to a subject of need. In some embodiments, the compounds described herein are administered to animals.
[0110] On the other hand, this document provides pharmaceutical compositions comprising the compounds described herein, or pharmaceutically acceptable salts or stereoisomers thereof, and at least one pharmaceutically acceptable excipient. The pharmaceutical compositions are formulated in a conventional manner using one or more pharmaceutically acceptable excipients that facilitate the processing of the active compound into a pharmaceutically acceptable formulation. A suitable formulation depends on the chosen route of administration. The summary of the pharmaceutical compositions described herein can be found in, for example, Remington: The Science and Practice of Pharmacy, 19th edition (Easton, Pa.: Mack Publishing Company, 1995); Hoover, John E., Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pennsylvania 1975; Liberman, HA and Lachman, L. (eds.), Pharmaceutical Dosage Forms, Marcel Decker, New York, NY, 1980; and Pharmaceutical Dosage Forms and Drug Delivery Systems, 7th edition (Lippincott Williams & Wilkins 1999), such publications being incorporated herein by reference. Example
[0111] The following embodiments are provided to illustrate, but not to limit, the claimed invention. These embodiments further illustrate the invention, but should not be construed as limiting its scope in any way.
[0112] The following synthetic schemes are provided for illustrative purposes and not for limitation. The following examples illustrate various methods for preparing the compounds described herein. It should be understood that those skilled in the art may be able to prepare these compounds by similar methods or by combining other methods known to them. It should also be understood that those skilled in the art will be able to prepare them in a manner similar to that described below, by using suitable starting materials and modifying the synthetic route as needed. Typically, starting materials and reagents are available from commercial suppliers, or synthesized from sources known to those skilled in the art, or prepared as described herein. Example A01
[0113] Sodium hydride (10.4 g, 260 mmol, 60% dispersed in mineral oil) was added to DMF (200 mL). The resulting mixture was stirred at -5°C for 10 minutes, and then ethyl 2-hydroxypropionate (40.1 g, 278 mmol) dissolved in DMF (50 mL) was slowly added at the same temperature. The resulting solution was stirred at the same temperature for 2 hours. At the same temperature, a suspension of tert-butyl 4-(2-ethoxy-2-oxoethylidene)piperidine-1-carboxylate (50.0 g, 186 mmol) in DMF (50 mL) was slowly added to the above solution. The resulting solution was heated and stirred at 25°C for 24 hours. The mixture was poured into a saturated aqueous solution of NH4Cl (500 mL) and extracted with EtOAc (500 mL × 3). The combined organic layers were washed with water (1 L × 3) and brine (500 mL × 2), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated to obtain crude product A01-1 (35.1 g), which was used directly in the next step without further purification. LCMS [M-Boc+H] + : 268.2.
[0114] To 5-bromo-2 H PPA (30 g) was added to an ethanol (200 mL) solution of 1,2,4-triazol-3-amine (11.88 g, 72.9 mmol) and crude A01-1 (33.4 g, 91 mmol). The mixture was stirred at 100°C for 48 hours. The mixture was cooled to room temperature, and then TEA (63.5 mL, 455 mmol) and (Boc)2O (63.5 mL, 273 mmol) were added. The resulting mixture was stirred at room temperature for 2 hours. The reaction mixture was concentrated under reduced pressure, diluted with water (300 mL), and extracted with EtOAc (300 mL × 2). The combined organic layers were washed with brine (200 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated and purified by silica gel chromatography to give A01-2. (9.8 g). LCMS [M-Boc+H] + 367.3.
[0115] Under a nitrogen atmosphere, NaH (60%, 643 mg, 16.08 mmol) was added fractionally to a stirred solution of A01-2 (5.0 g, 10.72 mmol) in DMF (50 mL) at -20°C. The reaction was heated to 0°C and stirred for 2 hours, followed by the slow addition of SEMCl (2.68 g, 16.08 mmol) at 0°C. The reaction was stirred at 0°C for 2 hours and then quenched with ice water (50 mL). The reaction was extracted with EtOAc (300 mL) to separate the organic phase. The organic phase was washed with brine (50 mL), dried over anhydrous Na2SO4, and filtered. The filtrate was concentrated and purified by silica gel chromatography to give A01-3 (4.3 g). LCMS [M-Boc+H] + : 496.2.
[0116] Peracetic acid (18% wt, 14.2 g, 33.52 mmol) was added to a stirred solution of A01-3 (4.0 g, 6.7 mmol) in DCM (200 mL). The reaction was stirred at room temperature for 2 days, then quenched with saturated NaHCO3 aqueous solution (20 mL) and Na2S2O3 aqueous solution (20 mL). The organic phase was separated, washed with brine (20 mL), dried over anhydrous Na2SO4, and filtered. The filtrate was concentrated and purified by silica gel chromatography to give A01-4 (1.1 g). LCMS [M-Boc+H] + : 512.2.
[0117] A solution of KF (1.42, 24.49 mmol) in water (6 mL) was added to a stirred solution of A01-4 (3.0 g, 4.9 mmol) in DMF (60 mL). The reaction was stirred overnight at 70°C. The reaction was cooled to room temperature and diluted with water (100 mL) and EtOAc (300 mL). The organic phase was separated, washed with brine (20 mL), dried over anhydrous Na2SO4, and filtered. The filtrate was concentrated and purified by silica gel chromatography to give A01-5 (2.3 g). LCMS [M-Boc+H] + : 382.1.
[0118] Add NaHCO3 aqueous solution (5%, 60 mL) and KBr (49 mg, 0.42 mmol) to a stirred solution of A01-5 (2.0 g, 4.2 mmol) in DCM (60 mL). N -methyl- N ,N -Dioctyloctyl-1-ammonium chloride (84 mg, 0.21 mmol) and TEMPO (36 mg, 0.21 mmol). The reaction was stirred at 0°C for 30 min, followed by the slow addition of NaClO aqueous solution (5%, 15.4 mL, 10.37 mmol). The reaction was stirred for 2 h. The pH of the reaction was adjusted to pH 3 by adding 1 N HCl. The organic phase was separated, and the aqueous phase was extracted with DCM (100 mL). The combined organic phases were washed with brine (20 mL), dried over anhydrous Na2SO4, and filtered. The filtrate was concentrated and purified by silica gel chromatography to give A01-6 (820 mg). LCMS [M-Boc+H] + : 396.1.
[0119] Et3N (1.63 g, 16.12 mmol) and T4P (2.74 g, 8.06 mmol) were added to a stirred solution of A01-6 (800 mg, 1.61 mmol) and 2-chloro-4-(trifluoromethyl)aniline (473 mg, 2.42 mmol) in THF (20 mL). The reaction was stirred at 50°C for 2 hours, then diluted with EtOAc (100 mL) and NaHCO3 aqueous solution (20 mL). The organic phase was separated, washed with brine (20 mL), dried over anhydrous Na2SO4, and filtered. The filtrate was concentrated and purified by silica gel chromatography to give A01-7 (421 mg). LCMS [M-Boc+H] + : 573.1.
[0120] Under a nitrogen atmosphere, K₂CO₃ (164 mg, 1.19 mmol), Pd(dppf)Cl₂ (43 mg, 0.06 mmol), and 2-(3,6-dihydro-2H-pyran-4-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborhexacyclopentane (150 mg, 0.712 mmol) were added to a stirred solution of A01-7 (400 mg, 0.59 mmol) in dioxane (50 mL) and water (5 mL). The reaction mixture was stirred at 90°C for 15 hours under a nitrogen atmosphere. The reaction mixture was diluted with EtOAc (200 mL) and water (50 mL). The organic phase was separated, washed with brine (20 mL), dried over anhydrous Na₂SO₄, and filtered. The filtrate was concentrated and purified by silica gel chromatography to give A01-8 (321 mg). LCMS [M-Boc+H] + : 577.2.
[0121] TFA (2 mL) was added to a 3 mL solution of DCM containing A01-8 (300 mg, 0.603 mmol). The mixture was stirred at room temperature for 1 hour. The reaction was concentrated to give A01-9 (151 mg). LCMS [M+H] + : 577.2.
[0122] To a DMF (3 mL) solution of A01-9 (100 mg, 0.173 mmol) and 3-hydroxypyridinecarboxylic acid (36 mg, 0.26 mmol), DIPEA (0.10 mL, 0.622 mmol) and HATU (132 mg, 0.132 mmol) were added. The mixture was stirred at room temperature for 0.5 h. The reaction was concentrated and purified by prep-HPLC to give A01 (12 mg). LCMS [M+H] + 698.2. Measurement Examples Determination of unwinding fluorescence intensity (FI)
[0123] The compound was added to a 384-well dilution plate, and each column was serially diluted in DMSO at a 1:3 ratio, for a total of 10 doses. Using an Echo, 0.15 μL of the diluted compound solution per row was transferred to the 384-well assay plate to achieve a final DMSO concentration of 1%, with two replicates per column. 5 μL of enzyme working solution was added to the 384-well assay plate, and the plate was centrifuged at 1000 rpm for 1 minute. A high control was set up with enzyme-containing DMSO, and a low control with enzyme-free DMSO. The plate was incubated at 25°C for 10 minutes, followed by the addition of 5 μL of ATP working solution and centrifugation at 1000 rpm for 1 minute. Then, 5 μL of dsDNA working solution was added and centrifuged at 1000 rpm for 1 minute. The final reaction was performed in assay buffer (containing 1 mM MgCl2) containing 0.5 nM enzyme, 10 nM dsDNA, and 50 μM ATP. After incubation at 25°C for 20 minutes, fluorescence intensity signals at Ex: 620 nm and Em: 685 nm were read using BMG (CLARIO Star Plusacu). The percentage of inhibition of the compound pores (% inh) was calculated = 100. (Mean high control - compound wells) / (Mean high control - mean low control). IC50 of the compounds was fitted using a nonlinear regression equation in XLfit 5.5.0. 50 . Table 5 A represents IC 50 < 100 nM, B indicates IC 50100-500 nM; C indicates IC 50 >500 nM. ADP-Glo Measurement
[0124] Add the compound to a 384-well dilution plate and serially dilute the compound in DMSO at a 1:3 ratio for each column, for a total of 10 doses. Transfer 0.1 μL of the diluted compound solution from each row to the 384-well assay plate using an Echo converter, resulting in a final DMSO concentration of 1%, with two replicates per column. Add 5 μL of enzyme working solution to the 384-well assay plate and centrifuge at 1000 rpm for 1 minute. Simultaneously, set up a high control with enzyme-containing DMSO and a low control with enzyme-free DMSO. Incubate at 25°C for 10 minutes. Add 5 μL of ATP and ssDNA working solution and centrifuge at 1000 rpm for 1 minute. The final reaction consists of 0.1 nM enzyme, 2.5 nM ssDNA, and 15 μM ATP in assay buffer (containing 2 mM MgCl2). After incubating at 25°C for 60 minutes, add 5 μL of ADP-Glo™ reagent solution and incubate at 25°C for 40 minutes. Dispense 10 μL of kinase assay reagent into each well and incubate at 25°C for 40 minutes. Read the luminescence signal using a BMG (PHERA star FSX) scanner. Calculate the inhibition percentage (% inh) of the compound wells = 100. (Mean high control - compound wells) / (Mean high control - mean low control). IC50 of the compounds was fitted using a nonlinear regression equation in XLfit 5.5.0. 50 . Table 6 A represents IC 50 < 100 nM, B indicates IC 50 100-500 nM; C indicates IC 50 >500 nM.
[0125] It should be understood that the embodiments and implementations described herein are for illustrative purposes only, and various modifications or changes will be suggested to those skilled in the art based thereon, and will be included within the spirit and scope of this application and the appended claims. All publications, patents and patent applications cited herein are incorporated herein by reference in their entirety for all purposes.
Claims
1. A compound of formula (I), or a pharmaceutically acceptable salt or stereoisomer thereof: Formula (V), in: X 1 X 2 X 3 X 4 X 5 and X 6 Each of these is independently C, CR, N, O, and S; Z is C(R) Z ) or N; R Z is H, CN, oxo (=O), -NO2, -OH, -OR a , -OC(=O)R a , -OC(=O)OR b , -OC(=O)NR c R d , -SF5, -SH, -SR a , -S(=O)R a , -S(=O)2R a , -S(=O)2NR c R d , -S(=O)(=NR b )R b , -NR c R d , -NR b C(=O)NR c R d , -NR b C(=O)R a , -NR b C(=O)OR b , -NR b S(=O)2R a , -N=S(=O)(R b )2, -C(=O)R a , -C(=O)OR b , -C(=O)NR c R d or -P(=O)(R b )2; R 1 It is a cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkyl, alkenyl, or alkynyl group, wherein each cycloalkyl, heterocycloalkyl, aryl, and heteroaryl group is independently and optionally influenced by one or more R groups. 1a replace; R 2 It is a cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkyl, alkenyl, or alkynyl group, wherein each cycloalkyl, heterocycloalkyl, aryl, and heteroaryl group is independently and optionally influenced by one or more R groups. 2a replace; Ring A is a cycloalkyl or heterocycloalkyl group, wherein the cycloalkyl and heterocycloalkyl groups are independently and optionally separated by one or more R groups. 1A replace; Ring B is a cycloalkyl or heterocycloalkyl group, wherein the cycloalkyl and heterocycloalkyl groups are independently and optionally separated by one or more R groups. 1B replace; The ring C is a cycloalkyl or heterocycloalkyl group, wherein the cycloalkyl and heterocycloalkyl groups are independently and optionally separated by one or more R groups. 1C replace; L is -C(O)-, -S(O)-, -S(O)2- or ; R 5 C 1-6 Alkyl, cycloalkyl, heterocyclic, aryl, or heteroaryl, wherein each alkyl, cycloalkyl, heterocyclic, aryl, and heteroaryl group is independently and optionally influenced by one or more R groups. 5a replace; R 1a R 2a R 1A R 1B R 1C and R 5a Each of these can be independently a halogen, -CN, -NO2, -OH, or -OR. a -OC(=O)R a -OC(=O)OR b -OC(=O)NR c R d -SF5, -SH, -SR a -S(=O)R a -S(=O)2R a -S(=O)2NR c R d -S(=O)(=NR) b )R b -NR c R d -NR b C(=O)NR c R d -NR b C(=O)R a -NR b C(=O)OR b -NR b S(=O)2R a -N=S(=O)(R b )2、-C(=O)R a -C(=O)OR b -C(=O)NR c R d -P(=O)(R b 2. C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is independently and optionally substituted by one or more R; Or two Rs on the same carbon 1a Together they form C2-C6 alkylidene groups that are optionally substituted with one or more R groups; Each R a Independently, it is a C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6 alkylene (cycloalkyl), C1-C6 alkylene (heterocycloalkyl), C1-C6 alkylene (aryl) or C1-C6 alkylene (heteroaryl), wherein each alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is independently and optionally substituted by one or more R; Each R b Independently, it is hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6 alkylene (cycloalkyl), C1-C6 alkylene (heterocycloalkyl), C1-C6 alkylene (aryl) or C1-C6 alkylene (heteroaryl), wherein each alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is independently and optionally substituted by one or more R; R c and R d Each of the following is independently hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6 alkylene (cycloalkyl), C1-C6 alkylene (heterocycloalkyl), C1-C6 alkylene (aryl) or C1-C6 alkylene (heteroaryl), wherein each alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is independently and optionally substituted by one or more R; or R c and R d Together with the atoms to which they are attached, they form heterocyclic alkyl groups optionally substituted with one or more R atoms; and Each R is independently a halogen, -CN, -OH, -SF5, -SH, -S(=O)C1-C3 alkyl, -S(=O)2C1-C3 alkyl, -S(=O)2NH2, -S(=O)2NHC1-C3 alkyl, -S(=O)2N(C1-C3 alkyl)2, -S(=O)(=NC1-C3 alkyl)(C1-C3 alkyl), -NH2, -NHC1-C3 alkyl, -N(C1-C3 alkyl)2, -N=S(=O)(C1-C3 alkyl) 2. -C(=O)C1-C3 alkyl, -C(=O)OH, -C(=O)OC1-C3 alkyl, -C(=O)NH2, -C(=O)NHC1-C3 alkyl, -C(=O)N(C1-C3 alkyl)2, -P(=O)(C1-C3 alkyl)2, C1-C3 alkyl, C1-C3 alkoxy, C1-C3 haloalkyl, C1-C3 haloalkoxy, C1-C3 hydroxyalkyl, C1-C3 aminoalkyl, C1-C3 heteroalkyl or C3-C6 cycloalkyl; Or two R atoms on the same atom can form an oxo group.
2. The compound according to claim 1, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein the compound is a compound of formula (Ia): Formula (Ia).
3. The compound according to claim 1 or 2, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein ring A is C 5- C 10 Cycloalkyl or 5- to 10-membered heterocycloalkyl, wherein the cycloalkyl and heterocycloalkyl are independently and optionally formed by one or more R 1A replace.
4. The compound according to any one of claims 1-3, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein each R 1A Independently halogen, -CN, -NO2, -OH, -OR a -SF5, -SH, -SR a -NR c R d C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 5- to 6-membered heterocyclic alkyl, phenyl or 5- to 6-membered heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic alkyl, aryl and heteroaryl is independently and optionally substituted by one or more R.
5. The compound according to any one of claims 1-4, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein ring B is C. 4- C 10 Cycloalkyl or 4- to 10-membered heterocyclic alkyl, wherein the cycloalkyl and heterocyclic alkyl are independently and optionally formed by one or more R 1B replace.
6. The compound according to any one of claims 1-5, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein each R 1B Independently halogen, -CN, -NO2, -OH, -OR a -SF5, -SH, -SR a -NR c R d C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 5- to 6-membered heterocyclic alkyl, phenyl or 5- to 6-membered heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic alkyl, aryl and heteroaryl is independently and optionally substituted by one or more R.
7. The compound according to any one of claims 1-6, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein the ring C is C 5- C 10 Cycloalkyl or 5- to 10-membered heterocycloalkyl, wherein the cycloalkyl and heterocycloalkyl are independently and optionally constituted by one or more (e.g., two or three, etc.) R 1C replace.
8. The compound according to any one of claims 1-7, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein each R 1C Independently halogen, -CN, -NO2, -OH, -OR a -SF5, -SH, -SR a -NR c R d C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 aminoalkyl, C1-C6 heteroalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 5- to 6-membered heterocyclic alkyl, phenyl or 5- to 6-membered heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic alkyl, aryl and heteroaryl is independently and optionally substituted by one or more R.
9. The compound according to any one of claims 1-8, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 1 For C3-C 12 Cycloalkyl, 3- to 12-membered heterocycloalkyl, C 6-12 Aryl, 5 to 12-membered heteroaryl, C1-C6 alkyl, C2-C6 alkenyl or C2-C6 ynyl, wherein each cycloalkyl, heterocycloalkyl, aryl and heteroaryl group is independently and optionally bound by one or more (e.g., two or three, etc.) R 1a replace.
10. The compound according to any one of claims 1-9, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein each R 1a Independently, it can be F, Cl, Br, I, CH3, CH2CH3, CF3, CF2H, CF2CF3, CH2CF3, SCF3, OCH3, OCH2CH3, OC2F5, OCF2Cl, SF5. , or .
11. The compound according to any one of claims 1-10, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 2 For C3-C 12 Cycloalkyl, 3- to 12-membered heterocycloalkyl, C 6-12 aryl, 5 to 12-membered heteroaryl, C1-C6 alkyl, C2-C6 alkenyl or C2-C6 ynyl, wherein each cycloalkyl, heterocycloalkyl, aryl and heteroaryl group is independently and optionally surrounded by one or more R 2a replace.
12. The compound according to any one of claims 1-11, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 5 C 1-6 Alkyl, C 3-12 Cycloalkyl, 3 to 12-membered heterocyclic groups, C 6-12 aryl or 5 to 12-membered heteroaryl, wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl group is independently and optionally bound by one or more R 5a replace.
13. The compound according to claim 1, or a pharmaceutically acceptable salt or stereoisomer thereof, selected from the compounds in Table 1 or Table 2.
14. A pharmaceutical composition comprising the compound of any one of claims 1-13, or a pharmaceutically acceptable salt or stereoisomer thereof, and a pharmaceutically acceptable excipient.
15. A method for inhibiting WRN activity in a subject in need, comprising administering to the subject in need the compound of any one of claims 1-13, or a pharmaceutically acceptable salt or stereoisomer thereof.
Citation Information
Patent Citations
Enhancement of the efficacy of nifedipine by deuteration
US5846514A
Method of using deuterated calcium channel blockers
US6334997B1
